



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 064 942 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

03.01.2001 Bulletin 2001/01

(51) Int. Cl.⁷: A61K 31/40, A61K 31/405,

A61K 9/22, A61K 47/38,

A61K 47/32, A61K 47/36,

A61K 47/40, A61K 47/14

(21) Application number: 99909332.1

(22) Date of filing: 25.03.1999

(86) International application number:

PCT/JP99/01499

(87) International publication number:

WO 99/49863 (07.10.1999 Gazette 1999/40)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
NL PT SE

Designated Extension States:

SI

(30) Priority: 26.03.1998 JP 7903998

29.06.1998 JP 18296398

(71) Applicant:

FUJISAWA PHARMACEUTICAL CO., LTD.
Osaka-shi Osaka 541-8514 (JP)

(72) Inventors:

- YAMASHITA, Kazunari
Muko-shi, Kyoto 617-0003 (JP)
- HASHIMOTO, Eiji
Hashimoto-shi, Wakayama 648-0015 (JP)
- NOMURA, Yukihiro
Osaka-shi, Osaka 545-0043 (JP)

• SHIMOJO, Fumio

Kawanishi-shi, Hyogo 666-0111 (JP)

• TAMURA, Shigeki

Osaka-shi, Osaka 533-0014 (JP)

• HIROSE, Takeo,

Chayamachi 525

Kyoto-shi, Kyoto 605-0933 (JP)

• UEDA, Satoshi

Kawanishi-shi, Hyogo 666-0125 (JP)

• SAITO, Takashi

Osaka-shi, Osaka 534-0002 (JP)

• IBUKI, Rinta

Kyoto-shi, Kyoto 603-8104 (JP)

• IDENO, Toshio

Takatsuki-shi, Osaka 569-1123 (JP)

(74) Representative:

Gille Hrabal Struck Neidlein Prop Roos
Patentanwälte,
Brucknerstrasse 20
40593 Düsseldorf (DE)**(54) SUSTAINED RELEASE PREPARATIONS**

(57) Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

EP 1 064 942 A1

Description**TECHNICAL FIELD**

5 [0001] The present invention relates to a formulation containing a macrolide compound and being endowed with an ability of an extremely excellent sustained-release, for use in a medical field.

BACKGROUND OF THE INVENTION

10 [0002] An oral formulation of one of macrolide compounds, namely tacrolimus with an useful immunosuppressive activity, has been prepared as a solid dispersion compositions, which possesses a rapid-release characterization by using polymers such as hydroxypropylmethyl cellulose and disintegrator (see for example EP 0 240 773). Owing to the presence of disintegrator therein, it is a rapid-release formulation. It has been appraised highly in clinical field owing to its high absorbability. In clinical practice, alternatively, the emergence of an oral tacrolimus formulation with a sufficient 15 long action and excellent oral absorbability has been expected. However, it is the state of the art for a person skilled in the art that the absorbability of a pharmaceutically active agent given orally in a manner as sustained-release formulation is generally reduced and/or that a non-negligible variation of the absorbability is observed. The inventors of the invention have carried out a lot of investigations. Consequently, the inventors have invented sustained-release formulations of macrolide compounds, the representative of which is tacrolimus, characterized in that macrolide compound is 20 excellently absorbed orally and/or that variation of its absorbability is suppressed.

DISCLOSURE OF THE INVENTION

[0003] The present invention relates to a sustained-release formulation of a macrolide compound, wherein the dissolution of the macrolide compound is under sustained release.

25 [0004] It is an object of the invention to provide a sustained-release formulation of a macrolide compound, wherein the time (T63.2%) required for 63.2 % of the maximum amount of macrolide compound to be dissolved is 0.7 to 15 hours, as measured according to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using a test solution which is an aqueous 0.005 % hydroxypropyl cellulose solution, adjusted to pH 4.5.

30 [0005] It is the other object of the invention to provide a solid dispersion composition of a macrolide compound usable in the sustained-release formulation mentioned above, wherein the macrolide compound is present as an amorphous state in a solid base.

[0006] It is a further object of this invention to provide a fine powder of a macrolide compound characterized by a particle diameter distribution within the range of 0.1~50 µm and/or a mean particle diameter within the range of 0.2~20 35 µm for use in the above-mentioned sustained-release formulation.

[0007] The T63.2% value as determined by the dissolution test in accordance with this invention can be estimated from the release curve constructed by plotting test data on graph paper. However, the release profile of a drug can be generally analyzed by fitting dissolution test data to a release model and such a method can also be used in the computation of said T63.2% value. The model for fitting which can be used includes the first-order or linear model, zero-order model, cube-root model, etc. as described in Yamaoka, K. & Yagahara, Y.: Introduction to Pharmacokinetics with a Microcomputer, Nankodo, p.138 but as a model by which all kinds of release patterns can be expressed with the highest validity, there is known Weibull function, which is described in the above book and L. J. Leeson & J. T. Carstensen (ed.): Release of Pharmaceutical Products (American Pharmaceutical Society) (Chizin Shokan), p.192-195.

[0008] Weibull function is a function such that the dissolution rate (%) in time (T) can be expressed by the following 45 equation:

$$\text{Dissolution rate (\%)} = D_{\max} \times \{1 - \exp[-((T - T_i)^n)/m]\}$$

where D_{\max} represents the maximum dissolution rate at infinite time, m is a scale parameter representing the dissolution velocity, n is a shape parameter representing the shape of the dissolution curve, T_i is a position parameter representing the lag time till start of dissolution, and the dissolution characteristic of a pharmaceutical product can be expressed by using those parameters in combination.

[0009] In order to fit dissolution test data to Weibull function and calculate the respective parameters, the nonlinear least square method described in Yamaoka, K. & Yagahara, Y.: Introduction to Pharmacokinetics with a Microcomputer, Nankodo, p.40, mentioned above, is used. More particularly, the parameters are determined at the point of time where the sum of the squares of differences between the values calculated by the above equation and the measured values at each point of time is minimal and the dissolution curve calculated by means of the above equation using those parameters is the curve which dose most faithfully represent the measured values.

- [0010] The meaning of each parameter of Weibull function is now explained.
- [0011] D_{\max} (maximum dissolution rate) is the maximum dissolution rate at infinity of time as mentioned above and generally the value of D_{\max} is preferably as close to 100 (%) as possible.
- [0012] m (scale parameter) is a parameter representing the dissolution velocity of a pharmaceutical product, and the smaller the value of m is, the higher is the dissolution velocity and similarly the larger the value of m is, the lower is the dissolution velocity.
- [0013] n (shape parameter) is a parameter representing the shape of a dissolution curve. When the value of n is 1, Weibull function can be written as dissolution rate (%) = $D_{\max} \times \{1-\exp[-(T-T_i)/m]\}$, and since this is equivalent to first-order kinetics, the dissolution curve is linear. When the value of n is smaller than 1, the dissolution curve plateaus off.
- [0014] T_i (position parameter) is a parameter representing the lag time till start of dissolution.
- [0015] The sustained-release formulation comprising a macrolide compound according to this invention can also be characterized by means of said Weibull function. Thus, the objective sustained-release formulation can be implemented by setting D_{\max} (maximum dissolution rate) at 80% or more, preferably 90% or more, more preferably 95% or more, m (scale parameter) at 0.7~20, preferably 1~12, more preferably 1.5~8, n (shape parameter) at 0.2~5, preferably 0.3~3, more preferably 0.5~1.5, and T_i (position parameter) at 0~12, preferably 0~8, and more preferably 0~4.
- [0016] The value found by substituting the parameter values of m and n from the above Weibull function into the term $m^{1/n}$ represents the time in which 63.2% of the maximum amount of dissolution of the active ingredient is released from the formulation (T63.2%). That is to say, $T63.2\text{ (hr)} = m^{1/n}$. The release characteristic of the sustained-release formulation of this invention can be evaluated by the Dissolution Test, Method 2 (Paddle method, 50 rpm) of JP XIII using a test solution which is 0.005% aqueous solution of hydroxypropyl cellulose adjusted at pH 4.5. In the sustained-release formulation comprising a macrolide compound according to this invention, the time(T63.2%) in which 63.2% of the maximum amount of the macrolide compound to be dissolved is released from the formulation is 0.7~15 hours. In the past, though the rapid-release formulation comprising macrolide compound has already been produced, any sustained-release formulations, T63.2% of which is 0.7~15 hours and which are quite useful in clinical practice, have never been produced. The present invention completed it for the first time. If the T63.2% value is shorter than 0.7 hour, the efficacy of the macrolide compound following oral administration will not be sufficiently sustained. When the formulation has a T63.2% value of more than 15 hours, the release of the active ingredient will be so retarded that the active ingredient will be eliminated from the body before the effective blood concentration is reached, thus being unsuited as the formulation of this invention. When T63.2% is 1.0~12 hours, a more favorable sustained-release can be achieved. More preferably, T63.2% is 1.3~8.2 hours, and the most preferred is a sustained-release formulation with a T63.2% value of 2~5 hours.
- [0017] The term "macrolide compound" for use in accordance with the invention is the generic name of compounds with 12 members or more, which belong to large-ring lactones. Abundant macrolide compounds generated by microorganisms of the genus Streptomyces, such as rapamycin, tacrolimus (FK506), and ascomycin, and the analogs and derivatives thereof are included in the term macrolide compound.
- [0018] As a particular example of the macrolide compound, the tricyclic compound of the following formula (I) can be exemplified.

40

45

50


55

5

10

15

20



(wherein each of adjacent pairs of R^1 and R^2 , R^3 and R^4 , and R^5 and R^6 independently

25

- (a) is two adjacent hydrogen atoms, but R^2 may also be an alkyl group or
- (b) may form another bond formed between the carbon atoms to which they are attached;

30

R^7 is a hydrogen atom, a hydroxy group, a protected hydroxy group, or an alkoxy group, or an oxo group together with R^1 ;

R^8 and R^9 are independently a hydrogen atom or a hydroxy group;

R^{10} is a hydrogen atom, an alkyl group, an alkyl group substituted by one or more hydroxy groups, an alkenyl group, an alkenyl group substituted by one or more hydroxy groups, or an alkyl group substituted by an oxo group;

35

X is an oxo group, (a hydrogen atom and a hydroxy group), (a hydrogen atom and a hydrogen atom), or a group represented by the formula $-CH_2O-$;

Y is an oxo group, (a hydrogen atom and a hydroxy group), (a hydrogen atom and a hydrogen atom), or a group represented by the formula $N-NR^{11}R^{12}$ or $N-OR^{13}$;

R^{11} and R^{12} are independently a hydrogen atom, an alkyl group, an aryl group or a tosyl group;

R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{22} and R^{23} are independently a hydrogen atom or an alkyl group;

40

R^{24} is an optionally substituted ring system which may contain one or more heteroatoms;

n is an integer of 1 or 2; and

45

in addition to the above definitions, Y , R^{10} and R^{23} , together with the carbon atoms to which they are attached, may represent a saturated or unsaturated 5- or 6-membered nitrogen, sulfur and/or oxygen containing heterocyclic ring optionally substituted by one or more groups selected from the group consisting of an alkyl, a hydroxy, an alkoxy, a benzyl, a group of the formula $-CH_2Se(C_6H_5)$, and an alkyl substituted by one or more hydroxy groups.

[0019] Preferable R^{24} may be cyclo(C_{5-7})alkyl group, and the following ones can be exemplified.

50

- (a) a 3,4-di-oxo-cyclohexyl group;
- (b) a 3- R^{20} -4- R^{21} -cyclohexyl group,
in which

55

R^{20} is hydroxy, an alkoxy group, an oxo group, or a $-OCH_2OCH_2CH_2OCH_3$ group, and
 R^{21} is hydroxy, $-OCN$, an alkoxy group, a heteroaryloxy which may be substituted by suitable substituents, a $-OCH_2OCH_2CH_2OCH_3$ group, a protected hydroxy group, chloro, bromo, iodo, aminoxyloxy, an azido group, p-tolyloxythiocarbonyloxy,
or $R^{25}R^{26}CHCOO-$,

in which

R²⁵ is optionally protected hydroxy or protected amino, and
R²⁶ is hydrogen or methyl, or

R²⁰ and R²¹ together form an oxygen atom in an epoxide ring; or

5

(c) cyclopentyl group substituted by methoxymethyl, optionally protected hydroxymethyl, acyloxymethyl

10

(in which the acyl moiety optionally contains either a dimethylamino group which may be quaternized, or a carboxy group which may be esterified), one or more amino and/or hydroxy groups which may be protected, or aminooxalyloxymethyl. A preferred example is a 2-formyl-cyclopentyl group.

[0020] The definitions used in the above general formula (I) and the specific and preferred examples thereof are now explained and set forth in detail.

[0021] The term "lower" means, unless otherwise indicated, a group having 1 to 6 carbon atoms.

15

[0022] Preferable examples of the "alkyl groups" and an alkyl moiety of the "alkoxy group" include a straight or branched chain aliphatic hydrocarbon residue, for example, a lower alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, neopentyl and hexyl.

20

[0023] Preferable examples of the "alkenyl groups" include a straight or branched chain aliphatic hydrocarbon residue having one double-bond, for example, a lower alkenyl group such as vinyl, propenyl (e.g., allyl group), butenyl, methylpropenyl, pentenyl and hexenyl.

[0024] Preferable examples of the "aryl groups" include phenyl, tolyl, xylyl, cumenyl, mesityl and naphthyl.

25

[0025] Preferable protective groups in the "protected hydroxy groups" and the protected amino are 1-(lower alkylthio)-(lower)alkyl group such as a lower alkylthiomethyl group (e.g., methylthiomethyl, ethylthiomethyl, propylthiomethyl, isopropylthiomethyl, butylthiomethyl, isobutylthiomethyl, hexylthiomethyl, etc.), more preferably C₁-C₄ alkylthiomethyl group, most preferably methylthiomethyl group;

trisubstituted silyl group such as a tri(lower)alkylsilyl (e.g., trimethylsilyl, triethylsilyl, tributylsilyl, tert-butyldimethylsilyl, tri-tert-butylsilyl, etc.) or lower alkyl-diarylsilyl (e.g., methyldiphenylsilyl, ethyldiphenylsilyl, propyldiphenylsilyl, tert-butyldiphenylsilyl, etc.), more preferably tri(C₁-C₄)alkylsilyl group and C₁-C₄ alkylidiphenylsilyl group, most preferably tert-butyldimethylsilyl group and tert-butyldiphenylsilyl group; and an acyl group such as an aliphatic, aromatic acyl

30

group or an aliphatic acyl group substituted by an aromatic group, which are derived from a carboxylic acid, sulfonic acid or carbamic acid.

[0026] Examples of the aliphatic acyl groups include a lower alkanoyl group optionally having one or more suitable substituents such as carboxy, e.g., formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, carboxyacetyl, carboxypropionyl, carboxybutyryl, carboxyhexanoyl, etc.;

35

a cyclo(lower)alkoxy(lower)alkanoyl group optionally having one or more suitable substituents such as lower alkyl, e.g., cyclopropoxyacetyl, cyclobutoxypiponyl, cycloheptyloxybutyryl, menthyloxyacetyl, menthyloxypropionyl, menthyl-oxybutyryl, menthyloxypentanoyl, menthyloxyhexanoyl, etc.; a camphorsulfonyl group; or a lower alkylcarbamoyl group having one or more suitable substituents such as carboxy or protected carboxy, for example, carboxy(lower)alkylcarbamoyl group (e.g., carboxymethylcarbamoyl, carboxyethylcarbamoyl, carboxypropylcarbamoyl, carboxybutylcarbamoyl, carboxypentylcarbamoyl, carboxyhexylcarbamoyl, etc.), tri-(lower)alkylsilyl(lower)alkoxycarbonyl(lower)alkylcarbamoyl group (e.g., trimethylsilylmethoxycarbonylethylcarbamoyl, trimethylsilylethoxycarbonylpropylcarbamoyl, triethylsilylethoxycarbonylpropylcarbamoyl, tert-butyldimethylsilylethoxycarbonylpropylcarbamoyl, tri-methylsilylpropoxy-carbonylbutylcarbamoyl, etc.) and so on.

40

[0027] Examples of the aromatic acyl groups include an aryl group optionally having one or more suitable substituents such as nitro, e.g., benzoyl, toluoyl, xyloyl, naphthoyl, nitrobenzoyl, dinitrobenzoyl, nitronaphthoyl, etc.; and an arenesulfonyl group optionally having one or more suitable substituents such as halogen, e.g., benzenesulfonyl, toluenesulfonyl, xylenesulfonyl, naphthalenesulfonyl, fluorobenzenesulfonyl, chlorobenzenesulfonyl, bromobenzenesulfonyl, iodobenzenesulfonyl, etc.

45

[0028] Examples of the aliphatic acyl groups substituted by an aromatic group include ar(lower)alkanoyl group optionally having one or more suitable substituents such as lower alkoxy or trihalo(lower)alkyl, e.g., phenylacetyl, phenylpropionyl, phenylbutyryl, 2-trifluoromethyl-2-methoxy-2-phenylacetyl, 2-ethyl-2-trifluoromethyl-2-phenylacetyl, 2-trifluoromethyl-2-propoxy-2-phenylacetyl, etc.

50

[0029] More preferable acyl groups among the aforesaid acyl groups are C₁-C₄ alkanoyl group optionally having carboxy, cyclo(C₅-C₆)alkoxy(C₁-C₄)alkanoyl group having two (C₁-C₄) alkyls at the cycloalkyl moiety, camphorsulfonyl group, carboxy-(C₁-C₄)alkylcarbamoyl group, tri(C₁-C₄)alkylsilyl(C₁-C₄)-alkoxycarbonyl (C₁-C₄)-alkylcarbamoyl group, benzoyl group optionally having one or two nitro groups, benzenesulfonyl group having halogen, or phenyl(C₁-C₄)alkanoyl group having C₁-C₄ alkoxy and trihalo(C₁-C₄)alkyl group. Among these, the most preferable ones are acetyl, carboxypropionyl, menthyloxyacetyl, camphorsulfonyl, benzoyl, nitrobenzoyl, dinitrobenzoyl, iodobenzenesulfo-

nyl and 2-trifluoromethyl-2-methoxy-2-phenylacetyl.


[0030] Preferable examples of the "5- or 6-membered nitrogen, sulfur and/or oxygen containing heterocyclic ring" include a pyrrolyl group and a tetrahydrofuryl group.

[0031] "A heteroaryl which may be substituted by suitable substituents" moiety of the "heteroaryloxy which may be substituted by suitable substituents" may be the ones exemplified for R¹ of the compound of the formula of EP-A-532,088, with preference given to 1-hydroxyethylindol-5-yl, the disclosure of which is incorporated herein by reference.

[0032] The tricyclic compounds (I) and its pharmaceutically acceptable salt for use in accordance with this invention are well known to have excellent immunosuppressive activity, antimicrobial activity and other pharmacological activities and, as such, be of value for the treatment or prevention of rejection reactions by transplantation of organs or tissues, graft-vs-host diseases, autoimmune diseases, and infectious diseases [EP-A-0184162, EP-A-0323042, EP-A-423714, EP-A-427680, EP-A-465426, EP-A-480623, EP-A-532088, EP-A-532089, EP-A-569337, EP-A-626385, WO89/05303, WO93/05058, WO96/31514, WO91/13889, WO91/19495, WO93/5059, etc.].

[0033] Particularly, the compounds which are designated as FR900506 (=FK506), FR900520 (ascomycin), FR900523, and FR900525 are products produced by microorganisms of the genus Streptomyces, such as Streptomy-

ces tsukubaensis No. 9993 [deposited with National Institute of Bioscience and Human Technology Agency of Industrial Science and Technology (formerly Fermentation Research Institute Agency of Industrial Science and Technology), at 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan, date of deposit October 5, 1984, accession number FERN BP-927] or Streptomyces hygroscopicus subsp. yakushimaensis No. 7238 [deposited with National Institute of Bioscience and Human Technology Agency of Industrial Science and Technology (formerly Fermentation Research Institute Agency of Industrial Science and Technology), at 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan, date of deposit January 12, 1985, accession number FERM BP-928][EP-A-0184162]. The FK506 (general name: tacrolimus) of the following chemical formula, in particular, is a representative compound.



Chemical name: 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

[0034] The preferred examples of the tricyclic compounds (I) are the ones, wherein each of adjacent pairs of R³ and R⁴ or R⁵ and R⁶ independently form another bond formed between the carbon atoms to which they are attached;

each of R⁸ and R²³ is independently a hydrogen atom;

R⁹ is a hydroxy group;

R¹⁰ is a methyl group, an ethyl group, a propyl group or an allyl group;

X is (a hydrogen atom and a hydrogen atom) or an oxo group;

Y is an oxo group;

each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²² is a methyl group;

R²⁴ is a 3-R²⁰-4-R²¹-cyclohexyl group,

in which

R²⁰ is hydroxy, an alkoxy group, an oxo group, or a -OCH₂OCH₂CH₂OCH₃ group, and

R^{23} is hydroxy, -OCN, an alkoxy group, a heteroaryloxy which may be substituted by suitable substituents, a -OCH₂OCH₂CH₂OCH₃ group, a protected hydroxy group, chloro, bromo, iodo, aminoxyloxy, an azido group, p-tolyloxythiocarbonyloxy, or R²⁵R²⁶CHCOO-,
in which

5

R²⁵ is optionally protected hydroxy or protected amino, and
R²⁶ is hydrogen or methyl, or

R²⁰ and R²¹ together form an oxygen atom in an epoxide ring; and

10

n is an integer of 1 or 2.

[0035] The most preferable tricyclic compounds(I) is, in addition to FK506, ascomycin derivatives such as halogenated-ascomycin (e.g., 33-epi-chloro-33-desoxyascomycin), which is disclosed in EP 427,680, example 66a.

15

[0036] As the other preferable example of the macrolides as immunosuppressants, rapamycin [THE MERCK INDEX (12th edition), No. 8288] and its derivatives can be exemplified. Preferred example of the derivatives is an O-substituted derivative in which the hydroxy in position 40 of formula A illustrated at page 1 of WO 95/16691, incorporated herein by reference, is replaced by OR₁ in which R₁ is hydroxylalkyl, hydroalkoxyalkyl, acylaminoalkyl and aminoalkyl; for example 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin and 40-O-(2-acetaminoethyl)-rapamycin. These O-substituted derivatives may be produced by reacting rapamycin (or dihydro or deoxo-rapamycin) with an organic radical attached to a leaving group (for example RX where R is the organic radical which is desired as the O-substituent, such as an alkyl, allyl, or benzyl moiety, and X is a leaving group such as CCl₃C(NH)O or CF₃SO₃) under suitable reaction conditions. The conditions may be acidic or neutral conditions, for example in the presence of an acid like trifluoromethanesulfonic acid, camphorsulfonic acid, p-toluenesulfonic acid or their respective pyridinium or substituted pyridinium salts when X is CCl₃C(NH)O or in the presence of a base like pyridine, a substituted pyridine, diisopropylethylamine or pentamethylpiperidine when X is CF₃SO₃. The most preferable one is 40-O-(2-hydroxy)ethyl rapamycin, which is disclosed in WO94/09010, the disclosure of which is incorporated herein by reference.

20

[0037] The tricyclic compounds(I), and rapamycin and its derivatives, have a similar basic structure, i.e., tricyclic

25

macrolide structure, and at least one of the similar biological properties (for example, immunosuppressive activity).

[0038] The tricyclic compounds(I), and rapamycin and its derivatives, may be in a form of its salt, which includes conventional non-toxic and pharmaceutically acceptable salt such as the salt with inorganic or organic bases, specifically, an alkali metal salt such as sodium salt and potassium salt, an alkali earth metal salt such as calcium salt and magnesium salt, an ammonium salt and an amine salt such as triethylamine salt and N-benzyl-N-methylamine salt.

30

[0039] With respect to the macrolide compound used in the present invention, it is to be understood that there may be conformers and one or more stereoisomers such as optical and geometrical isomers due to asymmetric carbon atom(s) or double bond(s), and such conformers and isomers are also included within the scope of macrolide compound in the present invention. And further, the macrolide compounds can be in the form of a solvate, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate.

35

[0040] One of preferable specific examples of the sustained-release formulation in accordance with the present invention is a formulation comprising a solid dispersion composition, wherein a macrolide compound is present as an amorphous state in a solid base, which shows its T_{63.2} is 0.7 to 15 hours. The presence or absence of a diffraction peak detected by X-ray crystallography, thermal analyses, and so on indicates whether or not a macrolide compound is present as an amorphous state in a solid base in the solid dispersion composition.

40

[0041] Any pharmaceutically acceptable base capable of retaining a macrolide compound as an amorphous state and being at a solid state at ambient temperature is satisfactory as the solid base for use in the solid dispersion composition mentioned above. Preferably, the solid base is a pharmaceutically acceptable water-soluble base; and more preferably, the base is for example one of the following water-soluble polymers:

45

polyvinylpyrrolidone (PVP), cellulose polymer [hydroxypropylmethyl cellulose (HPMC), hydroxypropylmethyl cellulose phthalate, methyl cellulose (MC), carboxymethyl cellulose sodium (CMC-Na), hydroxyethyl cellulose, hydroxypropyl cellulose (HPC), etc.], pectin, cyclodextrins, galactomannan, polyethylene glycol (PEG) with a mean molecular weight of 4000 or more, gelatin, etc.

50

[0042] For use, furthermore, the water-soluble polymers are individually used singly or in a mixture of two or more thereof. A more preferable water-soluble base is cellulose polymer or PVP; and the most preferable water-soluble base is HPMC, PVP or a combination thereof. In particular, HPMC of a type with a low viscosity can exert a more desirable sustained-release effect, when used; an aqueous 2% solution of the type of HPMC is at a viscosity of 1 to 4,000 cps,

preferably 1 to 50 cps, more preferably 1 to 15 cps, as measured at 20 °C by a viscometer of Brookfield type; in particular, HPMC 2910 at a viscosity of 3 cps (TC-5E, EW, Shin-estu Chemical Co., Ltd.) is preferable.

[0043] The weight ratio of the macrolide compound and such water-soluble base is preferably 1 : 0.05 to 1 : 2, more preferably 1 : 0.1 to 1 : 1, most preferably 1 : 0.2 to 1 : 0.4.

5 [0044] The solid base is additionally exemplified by water-insoluble pharmaceutically acceptable bases capable of retaining the macrolide compound as an amorphous state and being at the solid state at ambient temperature. More specifically, the solid base includes for example wax and water-insoluble polymers.

10 [0045] Specifically, preferable examples of wax include glycerin monostearate and sucrose fatty acid esters [for example, mono-, di- or triesters of sucrose with moderate to higher fatty acids, with 8 to 20 carbon atoms, for example caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachic acid, behenic acid, oleic acid, linoleic acid, etc.). Additional examples of wax include polyglycerin fatty acid ester. Any polyglycerin fatty acid ester including monoester, diester or polyester of polyglycerin with fatty acid is satisfactory. Specific examples of polyglycerin fatty acid ester include for example behenate hexa(tetra)glyceride, caprylate mono(deca)glyceride, caprylate di(tri)glyceride, caprate di(tri)glyceride, laurate mono(tetra)glyceride, laurate mono(hexa)glyceride, laurate mono(deca)glyceride, oleate mono(tetra)glyceride, oleate mono(hexa)glyceride, oleate mono(deca)glyceride, oleate di(tri)glyceride, oleate di(tetra)glyceride, oleate sesqui(deca)glyceride, oleate penta(tetra)glyceride, oleate penta(hexa)glyceride, oleate deca(deca)glyceride, linoleate mono(hepta)glyceride, linoleate di(tri)glyceride, linoleate di(tetra)glyceride, linoleate di(hexa)glyceride, stearate mono(di)glyceride, stearate mono(tetra)glyceride, stearate mono (hexa)glyceride, stearate mono(deca)glyceride, stearate tri(tetra)glyceride, stearate tri(hexa)glyceride, stearate sesqui (hexa)glyceride, stearate penta(tetra)glyceride, stearate penta(hexa)glyceride, stearate deca(deca)glyceride, palmitate mono(tetra)glyceride, palmitate mono(hexa)glyceride, palmitate mono(deca)glyceride, palmitate tri(tetra)glyceride, palmitate tri(hexa)glyceride, palmitate sesqui(hexa)glyceride, palmitate penta(tetra)glyceride, palmitate penta(hexa)glyceride, and palmitate deca(deca)glyceride. Preferable polyglycerin fatty acid esters are for example behenate hexa(tetra)glyceride [for example, Poem J-46B under a trade name, manufactured by Riken Vitamin Co., Ltd.], stearate penta(tetra)glyceride [for example, PS-310 under a trade name, manufactured by Sakamoto Yakuhin Kogyo Co., Ltd.], stearate mono(tetra)glyceride [for example, MS-310 under a trade name, manufactured by Sakamoto Yakuhin Kogyo Co., Ltd.], stearate penta(hexa)glyceride [PS-500 under a trade name, manufactured by Sakamoto Yakuhin Kogyo Co., Ltd.], stearate sesqui(hexa)glyceride [SS-500 under a trade name, manufactured by Sakamoto Yakuhin Kogyo Co., Ltd.], stearate mono(deca)glyceride and a mixture thereof. More preferable waxes are glycerin monostearate and low-HLB sucrose fatty acid ester [for example, F-50, F-20, F-10, etc., manufactured by Dai-ichi Kogyo Seiyaku, Co., Ltd.].

25 [0046] The weight ratio of the macrolide compound and wax is preferably 1 : 10 to 1 : 100, more preferably 1 : 40 to 1 : 60, when the wax is for example glycerin monostearate; the weight ratio thereof is preferably 1 : 0.2 to 1 : 20, more preferably 1 : 0.5 to 1 : 5, when the wax is for example sucrose fatty acid ester; the weight ratio thereof is preferably 1 : 0.1 to 1 : 100, more preferably 1 : 0.5 to 1 : 50, when the wax is polyglycerin fatty acid ester.

30 [0047] Preferable water-insoluble polymers include for example ethylcellulose, methacrylate copolymers (for example, Eudragits such as Eudragit E, R, S, RS, LD, etc.). In case that water-insoluble polymers is ethylcellulose, a pharmaceutically acceptable one can be used in the present invention. However, its preferable viscosity is 3 to 110 cps, more preferably 6 to 49 cps, most preferably 9 to 11 cps, when the viscosity of 5% ethylcellulose-toluene/ethanol (80/20) solution is measured by a viscosity test described in USP 23, NF18. For example, the preferable one is ETHOCELL (viscosity: 10) (trademark, Dow Chemical(US)).

35 [0048] The weight ratio of the macrolide compound and the water-insoluble polymer is preferably 1 : 0.01 to 1 : 10, more preferably 1 : 0.1 to 1 : 5; most preferably 1 : 0.1 to 1 : 1, when the water-insoluble polymer is ethylcellulose; the weight ratio thereof is most preferably 1 : 0.5 to 1 : 5, when the water-insoluble polymer is a methacrylate copolymer.

40 [0049] When preparing the solid dispersion composition of the present invention, the above solid base, such as water-soluble base and water-insoluble base, may be usable by singly or in combination thereof. In case the water-insoluble base is adopted as the solid base in the present invention, suitable dissolution profile of the solid dispersion composition can be achieved by mixing a suitable amount of water-soluble base, such as water-soluble polymer (e.g., HPMC). If desired, other than the solid base described above, suitable excipients (lactose, etc.), binders, coloring agents, sweeteners, flavor, diluents, antioxidants (vitamin E, etc.) and lubricants (for example, synthetic aluminium silicate, magnesium stearate, calcium hydrogen phosphate, calcium stearate, talc, etc.) for common use, are added to prepare a solid dispersion composition.

45 [0050] Depending on the type of the solid base, additionally, the dissolution rate of the macrolide compound from the solid dispersion composition is sometimes too slow or the initial dissolution rate thereof is sometimes required to be elevated. In that case, the dissolution rate of the macrolide compound from the solid dispersion composition can be adjusted, by adding appropriate disintegrators [for example, cross carmellose sodium (CC-Na), carboxymethyl cellulose calcium (CM-Ca), lowly substituted hydroxypropyl cellulose (L-HPC), starch sodium glycolate, micro-fine crystal cellulose, cross povidone, etc.] or appropriate surfactants [for example, hardened polyoxyethylene castor oil, polyoxyl stearate 40, polysorbate 80, sodium lauryl sulfate, sucrose fatty acid ester (HLB is more than 10), etc] to the solid dispersion

composition. When the solid base is a water-soluble base, however, the solid dispersion composition preferably does not substantially contain any disintegrator when preparing the sustained-release formulation of the present invention.

[0051] The particle size of the solid dispersion composition where the macrolide compound is present as an amorphous state in the solid base is preferably equal to or smaller than 500 µm. More preferably, the composition is of a particle size passing through a 350-µm, most preferably 250-µm sieve.

[0052] Furthermore, the solid dispersion composition of a macrolide compound comprised in the sustained-release formulation in accordance with the invention can be produced by methods described in EP 0 240 773 and WO 91/19495 and the like; the methods are more specifically described below.

[0053] The macrolide compound is dissolved in an organic solvent (for example, ethanol, dichloromethane or an aqueous mixture thereof, etc.), followed by addition of an appropriate amount of a solid base, and the resulting mixture is sufficiently dissolved or suspended together or is allowed to swell. Then, the mixture is sufficiently kneaded together. After removing the organic solvent from the mixture, the residue is dried and ground and is then subjected to size reduction, whereby a solid dispersion composition can be prepared, where the macrolide compound is present as an amorphous state in the solid base. During the kneading process, furthermore, lubricants such as calcium hydrogen phosphate, excipients such as lactose, and the like can further be added to the mixture, if necessary.

[0054] The sustained-release formulation comprising a macrolide compound in accordance with this invention can also be manufactured by using a finely divided powder of the macrolide compound. The particle size control of the macrolide compound can be effected by means of milling machinery which is of routine use in pharmaceutical industry, such as a pin mill, hammer mill, jet mill, and dry or wet ball-mill, to name but a few examples. The macrolide compound fine powder should have a particle diameter distribution within the range of 0.1~50 µm, preferably 0.2~20 µm, and more preferably 0.5~10 µm, and/or a mean particle diameter of 0.2~20 µm, preferably 0.5~10 µm, and more preferably 1~5 µm.

[0055] The dispersion solid composition and the fine powder of the macrolide compound, thus produced by the above methods, can be used as such as a sustained-release formulation. Taking account of handleability as a formulation, dispersibility in water, and dispersibility after oral dosing, the composition is more preferably prepared as a sustained-release formulation in a form of powder, fine powder, granule, tablet or capsule by routine formulation methods (e.g., compression molding).

[0056] If desired, then, the sustained-release formulation can be prepared by mixing the solid dispersion composition or fine powder of macrolide compounds, with, for example, diluents or lubricants (such as sucrose, lactose, starch, crystal cellulose, synthetic aluminium silicate, magnesium stearate, calcium stearate, calcium hydrogen phosphate, and talc) and/or coloring agents, sweeteners, flavor and disintegrators for routine use. The resulting mixture is then thoroughly mixed together to prepare a sustained-release formulation. The sustained-release formulation, or the solid dispersion composition or fine powder of macrolide compound of the present invention can be preliminarily dispersed in water and juice, to be orally given as a liquid formulation.

[0057] The effective dose of the macrolide compound varies, depending on the type of the compound, the age of a patient, his (her) disease, the severity thereof, or other factors. Generally, the effective ingredient is used at a dose of about 0.001 to 1,000 mg, preferably 0.01 to 500 mg, more preferably 0.1 to 100 mg per day for the therapeutic treatment of the disease; generally, a mean single dose is about 0.01 mg, 0.1 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg, and 500 mg.

[0058] After oral administration, the sustained-release formulation of the macrolide compound in accordance with the invention characteristically releases the macrolide compound in a sustained manner and the pharmaceutical activity maintains for a long period. In accordance with this invention, the frequency of administration of pharmacologically active macrolide compounds can be decreased. More particularly, it has become possible to provide a macrolide-containing pharmaceutical formulation which may be administered only once a day. Furthermore, it is by now possible to provide a pharmaceutical composition which is free from the risk for undesired effects caused by a transiently excessive concentration and insures an expression of pharmacological efficacy over a sufficiently extended period of time.

[0059] The sustained-release formulation of the present invention is useful for treatment and/or prevention of the following diseases and conditions because of the pharmacological activities possessed by the said macrolide compounds, particularly by the tricyclic compounds (I).

Rejection reactions by transplantation of organs or tissues such as the heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limb, muscle, nerve, intervertebral disc, trachea, myoblast, cartilage, etc.; graft-versus-host reactions following bone marrow transplantation; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, etc.; and infections caused by pathogenic microorganisms (e.g. Aspergillus fumigatus, Fusarium oxysporum, Trichophyton asteroides, etc.); inflammatory or hyperproliferative skin diseases or cutaneous manifestations of immunologically-mediated dis-

eases (e.g. psoriasis, atopic dermatitis, contact dermatitis, eczematoid dermatitis, seborheic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, erythema, dermal eosinophilia, lupus erythematosus, acne, and alopecia areata);

5 autoimmune diseases of the eye (e.g. keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, etc.);

10 reversible obstructive airways diseases [asthma (e.g. bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, and dust asthma), particularly chronic or inveterate asthma (e.g. late asthma and airway hyper-responsiveness) bronchitis, etc.];

mucosal or vascular inflammations (e.g. gastric ulcer, ischemic or thrombotic vascular injury, ischemic bowel diseases, enteritis, necrotizing enterocolitis, intestinal damages associated with thermal burns, leukotriene B4-mediated diseases);

15 intestinal inflammations / allergies (e.g. coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis);

food-related allergic diseases with symptomatic manifestation remote from the gastrointestinal tract (e.g. migraine, rhinitis and eczema);

20 renal diseases (e.g. intestinal nephritis, Goodpasture's syndrome, hemolytic uremic syndrome, and diabetic nephropathy);

nervous diseases (e.g. multiple myositis, Guillain-Barre syndrome, Meniere's disease, multiple neuritis, solitary neuritis, cerebral infarction, Alzheimer's diseases, Parkinson's disease, amyotrophic lateral sclerosis(ALS) and radiculopathy);

25 cerebral ischemic disease(e.g., head injury, hemorrhage in brain(e.g., subarachnoid hemorrhage, intracerebral hemorrhage), cerebral thrombosis, cerebral embolism, cardiac arrest, stroke, transient ischemic attack (TIA), hypertensive encephalopathy, cerebral infarction);

endocrine diseases (e.g. hyperthyroidism, and Basedow's disease);

hematic diseases (e.g. pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, and anerythroplasia);

30 bone diseases (e.g. osteoporosis);

respiratory diseases (e.g. sarcoidosis, pulmonary fibrosis, and idiopathic interstitial pneumonia);

skin diseases (e.g. dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photosensitivity, and cutaneous T-cell lymphoma);

35 circulatory diseases (e.g. arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, and myocarditis);

collagen diseases (e.g. scleroderma, Wegener's granuloma, and Sjogren's syndrome);

adiposis;

eosinophilic fasciitis;

40 periodontal diseases (e.g. damage to gingiva, periodontium, alveolar bone or substantia ossea dentis);

nephrotic syndrome (e.g. glomerulonephritis);

male pattern alopecia, alopecia senile;

muscular dystrophy;

pyoderma and Sezary syndrome;

45 chromosome abnormality-associated diseases (e.g. Down's syndrome);

Addison's disease;

active oxygen-mediated diseases [e.g. organ injury (e.g. ischemic circulation disorders of organs (e.g. heart, liver, kidney, digestive tract, etc.) associated with preservation, transplantation, or ischemic diseases (e.g. thrombosis, cardiac infarction, etc.));

intestinal diseases (e.g. endotoxin shock, pseudomembranous colitis, and drug- or radiation-induced colitis);

50 renal diseases (e.g. ischemic acute renal insufficiency, chronic renal failure);

pulmonary diseases (e.g. toxicosis caused by pulmonary oxygen or drugs (e.g. paracort, bleomycin, etc.), lung cancer, and pulmonary emphysema);

ocular diseases (e.g. cataracta, iron-storage disease (siderosis bulbi), retinitis, pigmentosa, senile plaques, vitreous scarring, corneal alkali burn);

55 dermatitis (e.g. erythema multiforme, linear immunoglobulin A bullous dermatitis, cement dermatitis);

and other diseases (e.g. gingivitis, periodontitis, sepsis, pancreatitis, and diseases caused by environmental pollution (e.g. air pollution), aging, carcinogen, metastasis of carcinoma, and hypobaropathy)];

diseases caused by histamine release or leukotriene C4 release;

restenosis of coronary artery following angioplasty and prevention of postsurgical adhesions; autoimmune diseases and inflammatory conditions (e.g., primary mucosal edema, autoimmune atrophic gastritis, premature menopause, male sterility, juvenile diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic ophthalmitis, lens-induced uveitis, idiopathic leukopenia, active chronic hepatitis, idiopathic cirrhosis, discoid lupus erythematosus, autoimmune orchitis, arthritis (e.g. arthritis deformans), or polyarthritis);
5 Human Immunodeficiency Virus (HIV) infection, AIDS; allergic conjunctivitis; hypertrophic cicatrix and keloid due to trauma, burn, or surgery.

- 10 [0060] In addition, the said tricyclic macrolides have liver regenerating activity and/or activities of stimulating hypertrophy and hyperplasia of hepatocytes. Therefore, the pharmaceutical composition of the present invention is useful for increasing the effect of the therapy and/or prophylaxis of liver diseases [e.g. immunogenic diseases (e.g. chronic autoimmune liver diseases such as autoimmune hepatic diseases, primary biliary cirrhosis or sclerosing cholangitis), partial liver resection, acute liver necrosis (e.g. necrosis caused by toxins, viral hepatitis, shock, or anoxia), hepatitis B, 15 non-A non-B hepatitis, hepatocirrhosis, and hepatic failure (e.g. fulminant hepatitis, late-onset hepatitis and "acute-on-chronic" liver failure (acute liver failure on chronic liver diseases))].
- [0061] And further, the present composition is also useful for increasing the effect of the prevention and/or treatment of various diseases because of the useful pharmacological activity of the said tricyclic macrolides, such as augmenting activity of chemotherapeutic effect, activity of cytomegalovirus infection, anti-inflammatory activity, inhibiting 20 activity against peptidyl-prolyl isomerase or rotamase, antimalarial activity, antitumor activity, and so on.
- [0062] This invention further provides a dissolution test method for a solid formulation comprising macrolide compound, which uses a test solution containing a suitable amount of cellulose polymer. In general, the dissolution test for testing a release characteristic of a medicinally active ingredient dissolved from a solid formulation containing it is carried out in accordance with Dissolution Test, Method 2 (Paddle method, 50 rpm), JP XIII, or Dissolution Test shown in 25 USP 23, NF18 or in European Pharmacopoeia (3rd edition). However, in conducting a dissolution test as to a formulation containing a small amount of a macrolide compound, the release of the macrolide compound based on the intrinsic content thereof may not reach 100% even after several hours. This is because, when the amount of the macrolide compound is small, adsorption of the macrolide compound on surfaces of the test vessel, filter, etc. will exert an influence of increased magnitude. After much investigation, the present inventors found that by adding a suitable amount of cellulose polymer (such as, HPMC, hydroxypropylcellulose phthalate, MC, CMC-Na, hydroxyethyl cellulose, hydroxypropyl 30 cellulose(HPC), and so on) to the test solution and by, if necessary, adding phosphoric acid or the like to the test solution so as to bring its pH to not higher than 7 in order to avoid the adverse effect of the consequent increase in pH on the stability of the macrolide compound, the influence of adsorption of the macrolide compound on surfaces of the test apparatus can be inhibited to achieve a recovery rate of substantially 100%. Preferable cellulose polymer is hydroxy- 35 propyl cellulose or its equivalent, the preferable viscosity of which is such that when its 5.0 g is dissolved in 95 ml of water, and after centrifugation to remove the foam where necessary, the viscosity of the solution is measured with a rotary viscometer at 25±0.1°C, the solution shows a viscosity of 75~150 cps. For example, the hydroxypropyl cellulose with an average molecular weight of about 100,000 as available from Aldrich corresponds thereto.
- [0063] The "suitable amount" of cellulose polymer to be added to the test solution is 0.001~0.1%, preferably 40 0.002~0.01%, and most preferably 0.005%, all based on the total amount of the test solution.
- [0064] Dissolution Test, Method 2 (Paddle method), JP XIII, and dissolution test shown in USP 23, NF18 or in European Pharmacopoeia (3rd edition) are well-known methods for testing the release kinetics of the active ingredient from a solid pharmaceutical product. They are dissolution tests using the specified vessel, paddle and other hardware, with a controlling quantity of test solution, temperature of test solution, rotational speed, and other conditions. Where necessary, the test is performed with the test solution adjusted to a suitable pH. In the present invention, pH is preferably not 45 higher than 7. In the present invention, "Dissolution Test, Method 2 (Paddle method, 50 rpm), JP XIII" means "Dissolution Test, Method 2 (Paddle method), JP XIII, which is carried out with stirring 50 revolutions per minute. The corresponding descriptions in JP XIII, USP 23 (NF18) and European Pharmacopoeia (3rd edition) is incorporated in this specification by reference.
- [0065] The invention will now be described in the following examples, but is not limited thereto. In the following 50 examples, FK506 is admixed as its monohydrate when preparing compositions containing it, though its amount is expressed as the weight of FK506, not of its monohydrate.

Example 1

[0066]

5

10

FK506	1.0 mg
HPMC 2910	1.0 mg
total	2.0 mg

[0067] FK506 was dissolved in ethanol, and to the resulting solution was added HPMC 2910 for allowing FK506 to sufficiently swell. Thereafter, the mixture was kneaded together. The resulting kneaded mixture was transferred to a stainless tray, dried in vacuo, and ground with a coffee mill. Subsequently, the resulting powder was subjected to size reduction by the following processes, to prepare solid dispersion composition (hereinafter referred as SDC) 1-1 to 1-6.

- (1) The ground powder was passed through a 250-µm sieve, and a fraction of those remaining on the sieve is designated as SDC 1-1 (> 250 µm).
- 20 (2) The fraction passing through the sieve at the process (1) was passed through a 180-µm sieve, and a fraction of those remaining on the sieve is designated as SDC 1-2 (180 - 250 µm).
- (3) The fraction passing through the sieve at the process (2) was passed through a 150-µm sieve, and a fraction of those remaining on the sieve is designated as SDC 1-3 (150 - 180 µm).
- 25 (4) The fraction passing through the sieve at the process (3) was passed through a 106-µm sieve, and a fraction of those remaining on the sieve is designated as SDC 1-4 (106 - 150 µm).
- (5) The fraction passing through the sieve at the process (4) was passed through a 75-µm sieve, and a fraction of those remaining on the sieve is designated as SDC 1-5 (75 - 106 µm).
- (6) The fraction passing through the sieve at the process (5) is designated as SDC 1-6 (< 75 µm).

30 Example 2

[0068] The SDC 1-2), which was obtained in Example 1, was sufficiently mixed with lactose (58.0 mg), and the resulting mixture was encapsulated, to prepare a capsule.

35 Example 3

[0069] In a similar manner to that of Example 1, a ground powder of the following SDC of particle sizes of 180 to 250 µm was prepared.

40

45

SDC	Macrolide compound	Water-soluble base
3-1)	FK506 (1.0 mg)	HPMC 2910 (0.3 mg)
3-2)	FK506 (1.0 mg)	HPMC 2910 (0.1 mg)

[0070] Furthermore, the SDC 3-1) was sufficiently mixed with lactose (58.7 mg), and the resulting mixture was encapsulated, to prepare capsule 3-1). The SDC 3-2) was sufficiently mixed with lactose (58.9 mg), and the resulting mixture was encapsulated to prepare capsule 3-2).

Example 4

[0071] In a similar manner to that for SDC 1-2) of Example 1, the following SDCs were prepared.

55

SDC	Macrolide compound	Water-soluble base
4-1) (2.0 mg in total)	FK506 (1.0 mg)	MC (1.0 mg)
4-2) (2.0 mg in total)	FK506 (1.0 mg)	PVP (1.0 mg)
4-3) (2.0 mg in total)	FK506 (1.0 mg)	HPMC 2910 (1.0 mg)
4-4) (2.0 mg in total)	FK506 (1.0 mg)	HPC (1.0 mg)
4-5) (2.0 mg in total)	FK506 (1.0 mg)	PEG (1.0 mg)
4-6) (2.0 mg in total)	FK506 (1.0 mg)	HPMC 2910 (0.8mg) PVP (0.2 mg)

5

10

15

[0072] In a similar manner to that of Example 2, lactose (at an appropriate amount) and magnesium stearate (0.6 mg) were added to the respective SDCs to prepare respective capsules, each of 60.0 mg in total.

20 Example 5

[0073] In a similar manner to that of the SDC 1-2) in Example 1, a SDC was prepared by using FK506 (1.0 mg) and HPMC 2910 (1.0 mg). In a similar manner to that of Example 2, thereafter, the following additives were respectively added to the SDC to prepare capsules 5-1) to 5-4), each of 60.0 mg in total.

25

30

35

40

Capsule No.	Additive(s)	
5-1)	crystal cellulose magnesium stearate	(appropriate amount) (0.6 mg)
5-2)	calcium hydrogen phosphate magnesium stearate	(appropriate amount) (0.6 mg)
5-3)	lactose L-HPC magnesium stearate	(appropriate amount) (3.0 mg) (0.6 mg)
5-4)	corn starch calcium stearate	(appropriate amount) (0.6 mg)

45 Example 6

[0074]

50

FK506	1.0 g
HPMC 2910	0.3 g
total	1.3 g

55

[0075] FK506 was dissolved in ethanol, and to the resulting solution was added HPMC 2910 to allow to sufficiently swell. Subsequently, the mixture was kneaded together. The resulting kneaded substance was transferred onto a stainless tray, dried in vacuo, and ground with a coffee mill. Subsequently, the resulting powder was subjected to size reduc-

EP 1 064 942 A1

tion by the following processes, to prepare SDCs 6-1) to 6-6).

- (1) The ground powder was passed through a 250- μm sieve, and a fraction of those remaining on the sieve is designated as SDC 6-1) ($> 250 \mu\text{m}$).
5 (2) The fraction passing through the sieve at the process (1) was passed through a 180- μm sieve, and a fraction of those remaining on the sieve is designated as SDC 6-2) (180 - 250 μm).
(3) The fraction passing through the sieve at the process (2) was passed through a 150- μm sieve, and a fraction of those remaining on the sieve is designated as SDC 6-3) (150 - 180 μm).
10 (4) The fraction passing through the sieve at the process (3) was passed through a 106- μm sieve, and a fraction of those remaining on the sieve is designated as SDC 6-4) (106 - 150 μm).
(5) The fraction passing through the sieve at the process (4) was passed through a 75- μm sieve, and a fraction of those remaining on the sieve is designated as SDC 6-5) (75 - 106 μm).
15 (6) The fraction passing through the sieve at the process (5) is designated as SDC 6-6).

15 Example 7

[0076] The SDC 6-4) (1.3 mg) which was obtained in Example 6 was mixed thoroughly with lactose (58.1 mg) and magnesium stearate (0.6 mg), and the resulting mixture was filled in capsules, which was defined as capsule 7.

20 Example 8

[0077] In a similar manner to that of Example 1, the following SDCs at particle sizes of 180-250 μm are prepared.

25

SDCs	Macrolide compound	Water-soluble base
8-1)	ascomycin (1.0 mg)	HPMC 2910 (0.3 mg)
8-2)	33-epi-chloro-33-desoxyascomycin (1.0 mg)	HPMC 2910 (0.3 mg)
8-3)	40-O-(2-hydroxy)-ethyl-rapamycin (1.0 mg)	HPMC 2910 (0.3 mg)

30

[0078] In a similar manner to that of Example 7, each capsule is prepared by adding lactose(58.1mg) and magnesium stearate(0.6mg).

35

Example 9

[0079]

40

SDC 9	
FK506	10 g
HPMC 2910	3 g
calcium hydrogen phosphate	3 g
total	16 g

50

55

Formulation 9	
SDC 9	16 g

(continued)

5

Formulation 9	
lactose	qs
magnesium stearate	7 g
total	700 g

[0080] FK506 was dissolved in ethanol, and HPMC 2910 is added to and mixed sufficiently with the resulting solution, followed by further addition of calcium hydrogen phosphate. After drying in vacuo overnight, the resulting mixture was subjected to size reduction by using a speed mill and a roll granulator; the resulting powder was sieved with a sieve of 212 µm; a fraction of those passing through the sieve is designated as SDC 9. The SDC 9, lactose and magnesium stearate were mixed together, to prepare Formulation 9. The Formulation 9 was filled at 350 mg in No. 1 capsule and at 70 mg in No. 5 gelatin capsule, which were defined as Formulations A and B, respectively.

15

Example 10

[0081]

20

25

SDC 10	
FK506	10 g
HPMC 2910	3 g
Lactose	3 g
total	16 g

30

35

40

Formulation 10	
SDC 10	16 g
lactose	qs
magnesium stearate	7 g
total	700 g

[0082] In a similar manner to that of example 9, the SDC 10 and Formulation 10 were prepared respectively.

45

Example 11

[0083]

50

55

SDC 11	
FK506	10 g
HPMC 2910	3 g
calcium hydrogen phosphate	3 g

(continued)

SDC 11	
total	16 g

5

10

Formulation 11	
SDC 11	16 g
lactose	qs
magnesium stearate	7 g
total	700 g

15

[0084] FK506 was dissolved in ethanol, and HPMC 2910 was added to and mixed sufficiently with the resulting solution, followed by further addition of calcium hydrogen phosphate. After the resulting mixture was dried in vacuo overnight, the mixture was subjected to size reduction by using a speed mill and a roll granulator; the resulting powder was sieved with a sieve of 250 µm and a sieve of 180 µm; a fraction of 180 - 250 µm is defined as SDC 11. The SDC 11, lactose and magnesium stearate were mixed together, to prepare Formulation 11. The Formulation 11 was filled at 350 mg in No. 1 capsule and at 70 mg in No. 5 gelatin capsule, which were defined as Formulations C and D, respectively.

Example 12

[0085]

30

35

SDC 12	
FK506	2 g
glycerin monostearate	98 g
HPMC 2910	20 g
total	120 g

40

45

Formulation 12	
SDC 12	120 g
magnesium stearate	1.2 g
total	121.2 g

50

[0086] Glycerin monostearate was heated and melt at 80°C, to which was added FK506 under agitation to dissolve FK506 therein. To the resulting mixture was added HPMC 2910 for sufficient mixing, and the resulting mixture was then transferred to a tray to stand alone for spontaneous cooling. The solid substance obtained by cooling was ground with a coffee mill and was then sieved with a sieve of 500 µm. A fraction of those passing through the sieve was defined as SDC 12. The SDC 12 was mixed with magnesium stearate, to prepare Formulation 12, which is then filled at 60.6 mg in No. 5 capsule. The resulting capsule is defined as Formulation E.

Example 13

[0087]

5

10

SDC 13	
FK506	2 g
Aminoalkyl methacrylate copolymer (Eudragit RL)	6 g
calcium hydrogen phosphate	2 g
total	10 g

15

20

25

Formulation 13	
SDC 13	10 g
lactose	130 g
total	140 g

[0088] In ethanol were dissolved FK506 and aminoalkyl methacrylate copolymer, followed by addition of calcium hydrogen phosphate, and the resulting mixture was sufficiently mixed together. The mixture was dried in vacuo overnight, ground in a mortar, and graded by using sieves of 150 µm and 106 µm, to prepare a fraction of 106 - 150 µm as SDC 13. The SDC 13 was mixed with lactose and prepared as Formulation 13, and was then filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation F.

Example 14

35 [0089]

40

45

50

SDC 14	
FK506	2 g
Aminoalkyl methacrylate copolymer (Eudragit RL)	4.6 g
Aminoalkyl methacrylate copolymer (Eudragit RS)	1.4 g
calcium hydrogen phosphate	2 g
total	10 g

55

Formulation 14	
SDC 14	10 g
lactose	130 g
total	140 g

EP 1 064 942 A1

[0090] In a similar manner to that of Example 13, SDC 14 at particle sizes of 106 - 150 µm and Formulation 14 were prepared. And then Formulation 14 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation G.

Example 15

5

[0091]

10

SDC 15	
FK506	2 g
Aminoalkyl methacrylate copolymer (Eudragit RL)	3 g
Aminoalkyl methacrylate copolymer (Eudragit RS)	3 g
calcium hydrogen phosphate	2 g
total	10 g

15

20

25

Formulation 15	
SDC 15	10 g
lactose	130 g
total	140 g

30

[0092] In a similar manner to that of Example 13, SDC 15 at particle sizes of 106 - 150 µm and Formulation 15 were prepared. And then Formulation 15 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation H.

35

Example 16

[0093]

40

SDC 16	
FK506	2 g
Ethylcellulose	0.4 g
lactose	6 g
total	8.4 g

45

50

55

Formulation 16	
SDC 16	8.4 g
lactose	131.6 g
total	140 g

EP 1 064 942 A1

[0094] In ethanol was dissolved FK506 and ethylcellulose, followed by addition of lactose, and the resulting mixture was sufficiently mixed together. The mixture was dried in vacuo overnight, ground in a mortar, and graded by using sieves of 150 µm and 106 µm, to prepare a fraction of 106 - 150 µm as SDC 16. The SDC 16 was mixed with lactose and prepared as Formulation 16, and was then filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation I.

5

Example 17

[0095]

10

15

SDC 17	
FK506	2 g
Ethylcellulose	1 g
lactose	6 g
total	9 g

20

25

30

Formulation 17	
SDC 17	9 g
lactose	131 g
total	140 g

[0096] In a similar manner to that of Example 16, SDC 17 at particle sizes of 106 - 150 µm and Formulation 17 were prepared. And then Formulation 17 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation J.

35

Example 18

[0097]

40

45

50

SDC 18	
FK506	2 g
Ethylcellulose	0.4 g
hydroxypropylmethyl cellulose	0.6 g
lactose	6 g
total	9 g

55

Formulation 18	
SDC 18	9 g

(continued)

5

Formulation 18	
lactose	131 g
total	140 g

[0098] In a similar manner to that of Example 16, SDC 18 at particle sizes of 106 - 150 µm and Formulation 18 were prepared. And then Formulation 18 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation K.

10

Example 19

[0099]

15

20

SDC 19	
FK506	2 g
Ethylcellulose	0.6 g
HPMC 2910	0.6 g
lactose	6 g
total	9.2 g

25

30

35

Formulation 19	
SDC 19	9.2 g
lactose	130.8 g
total	140 g

[0100] In a similar manner to that of Example 16, SDC 19 at particle sizes of 106 - 150 µm and Formulation 19 were prepared. And then Formulation 19 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation L.

40

Example 20

[0101]

45

50

55

SDC 20	
FK506	10 g
Ethylcellulose	3 g
HPMC 2910	3 g
lactose	50 g
total	66 g

5

Formulation 20	
SDC 20	66 g
lactose	qs
magnesium stearate	7 g
total	700 g

10

[0102] FK506 was dissolved in ethanol, and ethylcellulose was added to and was solved. And HPMC 2910 and lactose were mixed sufficiently with the resulting solution. After drying in vacuo overnight, the resulting mixture was subjected to size reduction by using a power mill and a roll granulator; the resulting powder was sieved with a sieve of 250 µm; a fraction of those passing through the sieve is designated as SDC 20. The SDC 20, lactose and magnesium stearate were mixed together, to prepare Formulation 20. The Formulation 20 was filled at 350 mg in No. 1 capsule and at 70 mg in No. 5 gelatin capsule, which were defined as Formulations M and N, respectively.

20 Example 21

[0103]

25

SDC 21	
FK506	10 g
Ethylcellulose	3 g
HPMC 2910	3 g
lactose	20 g
total	36 g

30

35

40

Formulation 21	
SDC 21	36 g
lactose	qs
magnesium stearate	7 g
total	700 g

45

[0104] In a similar manner to that of Example 20, a fraction of those passing through the sieve 212 µm was designated as SDC 21 and Formulation 21 were prepared. And then Formulation 21 was filled at 350 mg in No. 1 gelatin capsule and at 70 mg in No. 5 gelatin capsule to be prepared as Formulation O and P, respectively.

55

Example 22

[0105]

5

SDC 22		
FK506		1 g
Sucrose fatty acid ester (HLB=6) (DK ester F-50)		1 g
total		2 g

10

15

20

Formulation 22	
SDC 22	2 g
lactose	68 g
total	70 g

25 [0106] In ethanol/acetone (1/1) was dissolved FK506. After heating its solution at 75°C, sucrose fatty acid ester was added to be solved and then cooled at room temperature. The mixture was dried in vacuo overnight, ground in a mortar, and graded by using sieves of 150 µm and 106 µm, to prepare a fraction of 106 - 150 µm as SDC 22. The SDC 22 was mixed with lactose and prepared as Formulation 22, and was then filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation Q.

30

Example 23

35

[0107]

SDC 23		
FK506		1 g
Sucrose fatty acid ester (HLB=6) (DK ester F-50)		0.75 g
Sucrose fatty acid ester (HLB=2) (DK ester F-20W)		0.25 g
total		2 g

45

50

Formulation 23	
SDC 23	2 g
lactose	68 g
total	70 g

55

[0108] In a similar manner to that of Example 22, SDC 13 at particle sizes of 106 - 150 µm and Formulation 23 were prepared. And then Formulation 23 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation R.

Example 24

[0109]

5

10

15

20

25

SDC 24	
FK506	1 g
Sucrose fatty acid ester (HLB=1) (DK ester F-10)	1 g
Lactose	1 g
total	3 g

Formulation 24	
SDC 24	3 g
lactose	67 g
total	70 g

[0110] In a similar manner to that of Example 22, SDC 24 at particle sizes of 106 - 150 µm and Formulation 24 were prepared. And then Formulation 24 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation S.

30 Example 25

[0111]

35

40

45

50

55

SDC 25	
FK506	1 g
Sucrose fatty acid ester (HLB=1) (DK ester F-10)	1 g
Lactose	3 g
total	5 g

Formulation 24	
SDC 24	5 g
Lactose	65 g
total	70 g

[0112] In a similar manner to that of Example 22, SDC 25 at particle sizes of 106 - 150 µm and Formulation 25 were prepared. And then Formulation 25 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation T.

Example 26

[0113]

5

SDC 26		
	FK506	1 g
10	Sucrose fatty acid ester (HLB=1) (DK ester F-10)	1 g
	Lactose	5 g
	total	7 g

15

20

Formulation 26		
	SDC 26	7 g
	Lactose	63 g
25	total	70 g

[0114] In a similar manner to that of Example 22, SDC 26 at particle sizes of 106 - 150 µm and Formulation 26 were prepared. And then Formulation 26 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation U.

30 Example 27

[0115]

35

SDC 27		
	FK506	1 g
40	Tetraglycerine trifatty acid ester	30 g
	Lactose	15 g
	total	46 g

45

Formulation 27		
	SDC 27	46 g
	Lactose	24 g
50	total	70 g

55

[0116] In tetraglycerine trifatty acid ester melted by heating at 80 °C was added and solved FK506 with mixing. Lactose was added thereto, mixed and then cooled spontaneously in a tray. The resulting solid substance was ground by a coffee mill, and graded by using sieves of 150 µm and 106 µm, to prepare a fraction of 106 - 150 µm as SDC 27. The

SDC 27 was mixed with lactose and prepared as Formulation 27, and then Formulation 27 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation V.

Example 28

5

[0117]

10

SDC 28	
FK506	1 g
Tetraglycerine trifatty acid ester	30 g
Polysorbate	0.3 g
total	31.3 g

15

20

25

Formulation 28	
SDC 28	31.3 g
Lactose	38.7 g
total	70 g

30

[0118] In a similar manner to that of Example 27, SDC 28 at particle sizes of 106 - 150 µm and Formulation 28 were prepared. And then Formulation 28 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation W.

Example 29

35 [0119]

40

SDC 29	
FK506	1 g
Tetraglycerine trifatty acid ester	1 g
Lactose	3 g
total	5 g

45

50

55

Formulation 29	
SDC 29	5 g
Lactose	65 g
total	70 g

[0120] Ethanol was added to tetraglycerine trifatty acid ester. The resulting mixture was melted by heating at 40 °C and FK506 was added and melted with mixing. Lactose was added thereto, mixed and then cooled spontaneously in a tray. The resulting solid substance was ground by a coffee mill, dried in vacuo overnight and graded by using sieves of 150 µm and 106 µm, to prepare a fraction of 106 - 150 µm as SDC 29. The SDC 29 was mixed with lactose and prepared as Formulation 29, and then Formulation 29 was filled at 70 mg in No. 5 gelatin capsule to be prepared as Formulation X.

Example 30

10 [0121]

Formulation 30	
FK506 fine powder	0.5 g
Lactose	29.2 g
Magnesium stearate	0.3 g
total	30 g

[0122] FK506 crystal was ground by a jet mill and was mixed with lactose and magnesium stearate to prepare Formulation 30. Then Formulation 30 was filled at 60 mg in No. 5 gelatin capsule to be prepared as Formulation Z. The range of particle size of FK506 fine powder ground by a jet mill was 1-10 µm and its mean particle size was about 3 µm.

Example 31

Dissolution test

30 Test sample:

[0123]

35 (1) Formulations A and C, which were prepared in Examples mentioned before.
 (2) Control formulation (rapid-release formulation), which is 1 mg capsule formulation comprising the following ingredients. It is prepared, in a similar manner to that of Examples 1 and 2 of WO 91/19495, by mixing ingredients (e) and (f) with the solid dispersion composition composed of the following ingredients (a) to (d), and by being encapsulated.

40

(a) tacrolimus (FK506)	1 mg
(b) hydroxypropylmethyl cellulose	1 mg
(c) lactose	2 mg
(d) cross carmellose sodium	1 mg
(e) lactose	59.35 mg
(f) magnesium stearate	0.65 mg.

Test method:

55 [0124] According to the Japanese Pharmacopoeia, the 13-edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using an aqueous 0.005 % hydroxypropyl cellulose solution, adjusted to pH 4.5 as a test solution, a test was conducted. The obtained data were shown in the following.

	Time (hr)	Formulation A (%)	Time (hr)	Formulation C (%)
5	0	0.0	0	0.0
	0.5	17.4	1	12.1
	1	35.6	2	30.9
10	2	57.6	4	55.9
	3	71.9	6	71.3
	4	80.9	8	81.6
15	6	89.7	10	87.0
	9	95.2	12	90.4
20	Time (hr)	Control(%)		
	0	0.0		
	0.17	30.1		
	0.5	68.4		
25	1	92.8		
	2	100.1		

Example 32

- 30 [0125] In a similar manner to that of Example 31, dissolution test was carried out. And thereby various parameters in Weibull function and T63.2% were obtained by calculation.

	Result Formulation	Dmax (%)	m	n	T i	T _{63.2%} (hr)
35	Capsule 7	101.7	2.69	1.18	0.0	2.3
	A	95.9	2.24	1.03	0.0	2.2
40	C	92.5	6.14	1.24	0.0	4.3
	E	101.6	1.93	0.60	0.0	3.0
	F	95.6	2.51	1.00	0.0	2.5
45	G	99.0	3.69	0.91	0.0	4.2
	H	88.8	6.34	0.88	0.0	8.2
	I	95.6	2.51	1.00	0.0	2.5
50	J	99.0	3.69	0.91	0.0	4.2
	K	101.2	1.69	0.80	0.0	1.9
	L	91.4	2.48	0.75	0.0	3.3
55	M	90.4	1.61	0.62	0.0	2.1
	O	83.9	2.5	0.67	0.0	3.9
	Q	104.7	1.89	0.93	0.0	2.0
	R	92.1	2.09	0.82	0.0	2.5

(continued)

Result Formulation	Dmax (%)	m	n	T i	T _{63.2%} (hr)
S	86.0	3.73	0.89	0.0	4.4
T	87.9	2.00	0.93	0.0	2.1
U	93.4	1.03	0.86	0.0	1.0
V	83.6	1.14	0.54	0.0	1.3
W	87.1	1.30	0.69	0.0	1.5
Z	85.7	1.98	0.75	0.0	2.5
Control	100.9	0.41	1.10	0.0	0.4

15 Example 33

Oral absorbability

Test sample:

20 [0126]

- (1) Formulations B and D, which were prepared in the Examples mentioned before.
 (2) Control formulation (the same as the control in Example 31)

25

Test Method:

[0127] The test samples were orally given to 6 cynomolgus monkeys (at 1 mg/monkey as an FK506 dose), to assay the blood FK506 concentration after administration. Seventeen hours prior to the administration, feeds were withdrawn from a feed table for cynomolgus monkeys of body weights around 6 kg. Then, the animals were starved until 12 hours passed after the administration. Water was fed ad libitum prior to the initiation of the test throughout the administration of the test samples and thereafter. At the dosing, water (20 ml) was simultaneously given to the animals. At predetermined intervals after dosing, 1 ml of blood was drawn from the forearm vein by using a sterile syringe into a plastic tube containing heparin and stored at about -80 °C until the assay of the drug concentration started. The whole blood drug concentration of FK506 was assayed by the FK506-specific enzyme immunoassay (EIA) known in JP-A-1-92659. The disclosure thereof is cited herein and encompassed within the description of the specification.

40

Mean value			
Time (hr)	Formulation B	Formulation D	control
0	0.00	0.00	0.00
0.5	0.44	0.28	0.91
1	2.59	1.03	3.02
2	4.26	2.27	7.13
4	3.89	3.14	3.27
6	3.48	4.42	3.85
8	3.47	4.12	2.63
10	3.70	4.06	2.48
12	3.73	4.10	2.51
14	3.85	4.13	2.27
16	3.60	4.75	2.20

(continued)

5

Mean value			
Time (hr)	Formulation B	Formulation D	control
18	2.96	3.95	1.76
24	2.21	2.57	1.32

[0128] The maximum blood concentration (Cmax) is defined as the maximum value of the whole blood drug. Tmax is the time required for reaching the maximum blood concentration. MRT is defined as the mean retention time. The area under the blood concentration-time curve (AUC) was calculated by the trapezoid method. And as an indicator of the variation of oral absorbability, CV (standard deviation/mean in %) was calculated.

15

20

25

Test results				
Test Samples (Formulation No.)	Cmax(ng/mL) (C.V.(%))	Tmax (hr) (C.V.(%))	MRT (hr) (C.V.(%))	AUC _{0-72hr} (ng · hr/mL) (C.V.(%))
B	5.51±1.02 (45.4)	8.2±2.9 (87.8)	21.1±0.5 (5.5)	126.3±22.2 (43.1)
D	5.48±0.94 (41.8)	10.0±2.7 (66.9)	22.6±1.0 (11.2)	144.3±21.0 (35.7)
Control	8.41±1.46 (42.6)	3.3±0.8 (62.2)	17.6±0.9 (12.7)	91.1±20.4 (54.9)

Example 34

[0129] According to a similar manner to that of Example 33, the oral absorbability of the various formulations of the present invention was carried out.

30

45

50

Results				
Test samples (Formulation No.)	Cmax (ng/mL) [CV%]	Tmax (hr) [CV%]	MRT (hr) [CV%]	AUC _{0-72hr} (ng · hr/mL) [CV%]
E	9.36±1.08 [28.4]	6.3±1.7 [67.5]	20.0±0.4 [5.1]	186.6±18.5 [24.3]
L	6.16±0.57 [22.6]	4.3±1.1 [61.4]	19.3±0.5 [6.9]	135.5±17.7 [31.9]
Q	4.70±0.39 [20.2]	5.0±1.7 [83.0]	21.4±1.6 [7.0]	122.6±10.2 [20.3]
Z	5.72±0.92 [39.3]	8.0±1.2 [35.4]	20.9±1.2 [13.7]	133.2±16.1 [29.6]
control	12.27±2.60 [51.8]	1.4±0.3 [46.5]	14.3±1.0 [17.7]	80.8±15.1 [45.8]

[0130] The above results show that the formulations adopted in the above experiments, after oral administration, have smaller Cmax, sufficiently prolonged Tmax and MRT than those of the rapid-release formulation (control). And compared with the rapid-release formulation, AUC shown by the above formulations are almost the same or more. Or the above sustained-release formulations have small variations in individuals of Cmax and/or AUC, compared with a rapid-release formulation.

55


[0131] In accordance with the invention of the present application, the small variation in individuals of the maximum blood concentration or area under the blood concentration time curve of the macrolide compound after oral dosing, compared with a rapid release formulation thereof can be determined, by using an indicator of the variation of the blood absorbability of the macrolide compound, namely standard deviation/mean (CV in %) of the maximum blood concentration or the area under the blood concentration time curve. The term "small variation" means a small CV value thereof; more specifically, the term means that the CV value is smaller than that of a rapid release formulation as described above.

[0132] The disclosure of the patents, patent application and references cited herein in the application is encom-

passed within the description of the specification.

Claims

- 5 1. A sustained-release formulation of a macrolide compound, wherein the time (T63.2%) required for 63.2 % of the maximum amount of macrolide compound to be dissolved is 0.7 to 15 hours, as measured according to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using a test solution which is an aqueous 0.005 % hydroxypropyl cellulose solution adjusted to pH 4.5.
- 10 2. The sustained-release formulation in Claim 1, wherein the macrolide compound is a tricyclic compound represented by the general formula I and a pharmaceutically acceptable salt thereof.



- 35 (wherein each of adjacent pairs of R¹ and R², R³ and R⁴, and R⁵ and R⁶ independently
- (a) is two adjacent hydrogen atoms, but R² may also be an alkyl group or
(b) may form another bond formed between the carbon atoms to which they are attached;
- 40 R⁷ is a hydrogen atom, a hydroxy group, a protected hydroxy group, or an alkoxy group, or an oxo group together with R¹;
- R⁸ and R⁹ are independently a hydrogen atom or a hydroxy group;
- R¹⁰ is a hydrogen atom, an alkyl group, an alkyl group substituted by one or more hydroxy groups, an alkenyl group, an alkenyl group substituted by one or more hydroxy groups, or an alkyl group substituted by an oxo group;
- 45 X is an oxo group, (a hydrogen atom and a hydroxy group), (a hydrogen atom and a hydrogen atom), or a group represented by the formula -CH₂O-;
- Y is an oxo group, (a hydrogen atom and a hydroxy group), (a hydrogen atom and a hydrogen atom), or a group represented by the formula N-NR¹¹R¹² or N-OR¹³,
- 50 R¹¹ and R¹² are independently a hydrogen atom, an alkyl group, an aryl group or a tosyl group;
- R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³ are independently a hydrogen atom or an alkyl group;
- R²⁴ is an optionally substituted ring system which may contain one or more heteroatoms;
- n is an integer of 1 or 2; and
- in addition to the above definitions, Y, R¹⁰ and R²³, together with the carbon atoms to which they are attached, 55 may represent a saturated or unsaturated 5- or 6-membered nitrogen, sulfur and/or oxygen containing heterocyclic ring optionally substituted by one or more groups selected from the group consisting of an alkyl, a hydroxy, an alkoxy, a benzyl, a group of the formula -CH₂Se(C₆H₅), and an alkyl substituted by one or more hydroxy groups.

3. The sustained-release formulation in Claim 1, which comprises a solid dispersion composition, wherein the macrolide compound is present as an amorphous state in a solid base.
4. A solid dispersion composition usable in the sustained-release formulation in Claim 3, wherein the macrolide compound is present as an amorphous state in a solid base.
5. The composition in Claim 4, wherein its particle size is equal to or smaller than 500 µm.
6. The composition in Claim 4, wherein the solid base is a water-soluble base and the weight ratio of the macrolide compound and the water-soluble base is 1 : 0.05 to 1 : 2.
7. The composition in Claim 4, wherein the water-soluble base is a water-soluble polymer.
8. The composition in Claim 7, wherein the water-soluble polymer is hydroxypropylmethyl cellulose.
9. The composition in Claim 4, wherein the composition does not substantially contain any disintegrator.
10. The composition in Claim 4, wherein the solid base is a water-insoluble base.
11. The composition in Claim 10, wherein the water-insoluble base is wax.
12. The composition in Claim 11, wherein the wax is the one selected from the group consisting glycerin monostearate, polyglycerin fatty acid ester and sucrose fatty acid ester.
13. The composition in Claim 10, wherein the water-insoluble base is a water-insoluble polymer.
14. The composition in Claim 13, wherein the weight ratio of the macrolide compound and the water-insoluble polymer is 1 : 0.01 to 1 : 10.
15. The composition in Claim 13, wherein the water-insoluble polymer is ethylcellulose.
16. The formulation in Claim 2 or the composition in Claim 4, wherein the macrolide compound is tacrolimus or a hydrate thereof.
17. The formulation in Claim 2 or the composition in Claim 4, wherein the macrolide compound is 33-epi-chloro-33-desoxyascomycin.
18. The formulation in Claim 1, which comprises fine powder of the macrolide compound characterized by a particle diameter distribution within the range of 0.1 to 50 µm and/or a mean particle diameter within the range of 0.2 to 20 µm.
19. The fine powder of the macrolide compound usable in the sustained-release formulation in Claim 1, which has a particle diameter distribution within the range of 0.1 to 50 µm and/or a mean particle diameter of 0.2 to 20 µm
20. A sustained-release formulation of a macrolide compound, the dissolution rate of which is expressed by the following equation:

$$\text{Dissolution rate (\%)} = D_{\max} \times \{1 - \exp[-((T - T_i)^n)/m]\}$$

, wherein T is a time for evaluation,

D_{max} (maximum dissolution rate) is 80% or more,
 m (scale parameter) is 0.7~20,
 n (shape parameter) is 0.2~5, and
 T_i (position parameter) is 0~12,

when the dissolution test therefor is performed according to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using a test solution which is an aqueous 0.005 % hydroxypropyl cel-

lulose solution adjusted to pH 4.5; and each parameters are calculated by a nonlinear least square method.

21. A dissolution test method for a solid formulation comprising macrolide compound, which uses a test solution containing a suitable amount of cellulose polymer.
5
22. The dissolution test method in Claim 21, in which cellulose polymer is hydroxypropyl cellulose or its equivalent and the concentration of which is 0.001 to 0.1%.
23. The dissolution test method in Claim 22, in which pH of the test solution was adjusted to not higher than 7.
10
24. The dissolution test method in Claim 21, in which the dissolution test is performed according to Dissolution Test, Method 2 (Paddle method, 50 rpm), JP XIII or dissolution test shown in USP 23, NF18 or European Pharmacopoeia (3rd edition).
- 15 25. The dissolution test method in Claim 21, wherein the solid formulation comprising the macrolide compound is a rapid-release formulation or sustained-release formulation comprising tacrolimus or a hydrate thereof.
26. The dissolution test method in Claim 22, wherein the level of addition of said hydroxypropyl cellulose or its equivalent is 0.005% and the test solution is adjusted to pH 4.5.
20

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT		International application No. PCT/JP99/01499
A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁶ A61K31/40, 31/405, 9/22, 47/38, 47/32, 47/36, 47/40, 47/14		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁶ A61K31/40, 31/405, 9/22, 47/38, 47/32, 47/36, 47/40, 47/14		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), REGISTRY (STN), MEDLINE (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, 62-277321, A (Fujisawa Pharmaceutical Co., Ltd.), 2 December, 1987 (02. 12. 87) & EP, 240773, A1 & US, 4916138, A	1-26
A	JP, 3-128320, A (Fujisawa Pharmaceutical Co., Ltd.), 31 May, 1991 (31. 05. 91) & EP, 406791, A1 & US, 5770607, A	1-26
A	JP, 9-501939, A (Sandoz Ltd.), 25 February, 1997 (25. 02. 97) & WO, 95/06464, A1 & EP, 716598, A1	1-26
A	JP, 3-232814, A (Shin-Etsu Chemical Co., Ltd.), 16 October, 1991 (16. 10. 91) & EP, 441245, A1	1-26
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 28 May, 1999 (28. 05. 99)	Date of mailing of the international search report 8 June, 1999 (08. 06. 99)	
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	
Facsimile No.	Telephone No.	



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 444 659 A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91102996.5

(51) Int. Cl. 5: A61K 31/71, A61K 47/44,
A61K 47/10, A61K 31/40,
A61K 31/445

(22) Date of filing: 28.02.91

(30) Priority: 01.03.90 JP 51110/90

(71) Applicant: FUJISAWA PHARMACEUTICAL CO.,
LTD.

(43) Date of publication of application:
04.09.91 Bulletin 91/36

4-7, Doshomachi 3-chome Chuo-ku
Osaka-shi Osaka 541(JP)

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE


(72) Inventor: Nakanishi, Shigeo
12-5, Shimokida-cho
Neyagawa-shi, Osaka 572(JP)
Inventor: Yamanaka, Iwao
5-6-12, Kamiminami, Hirano-ku
Osaka-shi, Osaka 547(JP)

(74) Representative: Türk, Gille, Hrabal
Brucknerstrasse 20
W-4000 Düsseldorf 13(DE)

(54) A pharmaceutical solution.

(57) A pharmaceutical solution which contains the compound of the general formula having the immusuppressive activity is disclosed.

EP 0 444 659 A2



Field of the Invention

The present invention relates to a pharmaceutical solution which contains the compound (I) or a pharmaceutically acceptable salt thereof described later that is known as showing immunosuppressive activity.


In detail, the present invention relates to the solution which shows long term storage stability in a nonaqueous solution and may be diluted with such as physiological saline, glucose solution for injection, water, fruit juice, and the like without occurrence of any precipitations of the compound(I).

Accordingly, the present invention relates to the above pharmaceutical solution which can be applied for various form of medicine such as intravenous injection, oral administrating liquidous medicine, or the like.

Prior Arts

The compound(I) used in the present invention is shown as follows.

15



40

wherein each vicinal pair of substituents [R¹ and R²], [R³ and R⁴], [R⁵ and R⁶] independently

- a) represent two vicinal hydrogen atoms, or
- b) form a second bond between the vicinal carbon atoms to which they are attached ;
in addition to its significance above, R² may represent an alkyl group ;

45

R<sup>7</sup>

represents H, OH, protected hydroxy or O-alkyl, or in conjunction with R¹ it may represent =O ;

independently represent H or OH ;

represents H, alkyl, alkyl substituted by one or more hydroxyl groups, alkenyl, alkenyl substituted by one or more hydroxyl groups, or alkyl substituted by =O ;

;

represents O, (H,OH), (H,H) or -CH₂O- ;

represents O, (H,OH), (H,H) or N-NR¹R¹² or N-OR¹³ ;

independently represent H, alkyl, aryl or tosyl ;

independently represent H or alkyl ;

independently represent O, or they may independently represent (R²⁰a, H) and (R²¹a, H) respectively ;

R²⁰a and R²¹a independently represent OH, O-alkyl

50

R<sup>8</sup> and R<sup>9</sup>

independently represent H or OH ;

represents H, alkyl, alkyl substituted by one or more hydroxyl groups, alkenyl, alkenyl substituted by one or more hydroxyl groups, or alkyl substituted by =O ;

;

represents O, (H,OH), (H,H) or -CH₂O- ;

represents O, (H,OH), (H,H) or N-NR¹R¹² or N-OR¹³ ;

independently represent H, alkyl, aryl or tosyl ;

independently represent H or alkyl ;

independently represent O, or they may independently represent (R²⁰a, H) and (R²¹a, H) respectively ;

R²⁰a and R²¹a independently represent OH, O-alkyl

55

X

Y

R<sup>11</sup> and R<sup>12</sup>

R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>22</sup> and R<sup>23</sup>

R<sup>20</sup> and R<sup>21</sup>

or $\text{OCH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$ or R^{21}a is protected hydroxy

- in addition, R^{20}a and R^{21}a may together represent an oxygen atoms in an epoxide ring ;
n is 1, 2 or 3 ;
5 in addition to their significances above, Y, R^{10} and R^{23} , together with the carbon atoms to which they are attached, may represent a 5- or 6- membered N-, S- or O-containing heterocyclic ring, which may be saturated or unsaturated, and which may be substituted by one or more groups selected from alkyl, hydroxy, alkyl substituted by one or more hydroxyl groups, O-alkyl, benzyl and $-\text{CH}_2\text{Se}(\text{C}_6\text{H}_5)$.

The compound (I) and its pharmaceutically acceptable salt have remarkable immunosuppressive, 10 antimicrobial and other pharmacologic activities and are known to be of value in the treatment and prevention of resistance to organ or tissue transplantation, graft-versus-host disease, various autoimmune disease and infectious disease (Japanese Kokai Patent Publication No. 61-148181/1986 and European Patent Publication No.0323042).

Such compound(I) and its pharmaceutically acceptable salt are prepared in the same manner as the 15 one described in the above-mentioned two patent applications. Particularly, the macrolides, which are produced by fermentation of *Streptomyces tsukubaensis* No.9993 (FERM BP-927) or *Streptomyces hygroscopicus* subsp. *yakushimaensis* No.7238 (FERM BP-928), are numbered FR-900506, FR-900520, FR-900523 and FR-900525.

It is considered to prepare various kind forms of medicine such as powder, suspension, pharmaceutical 20 solution which contains the compound (I) and pharmaceutically acceptable salt thereof (hereinafter the term "compound (I)" is representatively used to show them). However it is difficult to prepare stable pharmaceutical solution of the compound(I), which causes a difficulty in applying the compound (I) for clinical use where it is desired to prepare pharmaceutical solution e.g., injection, oral administrating liquid, local scattering solution, dropping lotion in the eye, and the like.

25 Object of the Invention

It is the object of the present invention to prepare pharmaceutical solution containing the compound (I).
In more detail it is the object of the present invention to prepare the above pharmaceutical solution 30 which shows clear aqueous solution state that is especially desired for intravenous injection.

Summary of the Invention

Pharmaceutical solution of the present invention comprises of the above compound (I) as an active 35 ingredient, a pharmaceutically acceptable surface active agent and nonaqueous solvent.

Detailed Description of the Invention

In the above and subsequent descriptions on the present invention, suitable examples and illustrations 40 of the various definitions which the present invention includes within the scope thereof are explained in detail as follows.

The term " lower " as used in this specification means, unless otherwise indicated, any number of carbon atoms between 1 and 6, inclusive.

Suitable " alkyl " means straight or branched saturated aliphatic hydrocarbon residue and may include 45 lower alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, neopentyl, hexyl, and the like.

Suitable " alkenyl " means straight or branched unsaturated aliphatic hydrocarbon residue having one double bond and may include lower alkenyl such as vinyl, propenyl, butenyl, methylpropenyl, pentenyl, hexenyl, and the like.

Suitable " aryl " may include phenyl, tolyl, xylyl, cumenyl mesityl, naphthyl, and the like.

50 Suitable examples of the protective group in the "protected hydroxyl group " may include :
1-(lower alkylthio)(lower)alkyl groups such as lower alkylthiomethyl groups (e.g. methylthiomethyl, ethylthiomethyl, propylthiomethyl, isopropylthiomethyl, butylthiomethyl, isobutylthiomethyl, hexylthiomethyl, etc.), more desirably $\text{C}_1 - \text{C}_4$ alkylthiomethyl groups, and most desirably methylthiomethyl; tri-substituted silyl groups such as tri(lower)-alkylsilyl groups (e.g. trimethylsilyl, triethylsilyl, tributylsilyl, tert-butyl-dimethylsilyl, tri-tert-butylsilyl, etc.);
lower alkyl-diarylsilyl groups (e.g. methyldiphenylsilyl, ethyldiphenylsilyl, propyldiphenylsilyl, tert-butyl-diphenylsilyl, etc.), more desirably tri($\text{C}_1 - \text{C}_4$)alkylsilyl and $\text{C}_1 - \text{C}_4$ alkylidiphenylsilyl groups and most desirably tert-butylidimethylsilyl and tert-butylidiphenylsilyl; and acyl groups such as aliphatic acyl groups,

aromatic acyl groups and aliphatic acyl groups substituted by aromatic groups, which are derived from carboxylic acids, sulfonic acids or carbamic acids.

The aliphatic acyl group may include lower alkanoyl groups which may optionally have one or more suitable substituents such as carboxy (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, carboxyacetyl, carboxypropionyl, carboxybutyryl, carboxyhexanoyl, etc.), cyclo(lower)-alkoxy - (lower)alkanoyl groups which may optionally have one or more appropriate substituents such as lower alkyl (e.g. cyclopropoxyacetyl, cyclobutoxypropionyl, cycloheptyloxybutyryl, menthyloxyacetyl, menthyloxypropionyl, menthyloxybutyryl, menthyloxpentanoyl, menthyloxyhexanoyl, etc.), camphorsulfonyl, lower alkylcarbamoyl groups having one or more suitable substituents such as carboxy or protected carboxy, for example carboxy(lower)alkylcarbamoyl groups (e.g. carboxymethylcarbamoyl, carboxyethylcarbamoyl, carboxypropylcarbamoyl, carboxybutylcarbamoyl, carboxypentylcarbamoyl, carboxyhexylcarbamoyl, etc.), protected carboxy(lower)alkylcarbamoyl groups such as tri(lower)alkylsilyl(lower)alkoxycarbonyl(lower)alkylcarbamoyl groups (e.g. trimethylsilylmethoxycarbonylethylcarbamoyl, trimethylsilylethoxycarbonylpropylcarbamoyl, triethylsilylethoxycarbonylpropylcarbamoyl, tert-butyldimethylsilylethoxycarbonylpropylcarbamoyl, trimethylsilylpropoxycarbonylbutylcarbamoyl, etc.) and so on.

The aromatic acyl group may include aryl groups which may optionally have one or more suitable substituents such as nitro (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, nitrobenzoyl, dinitrobenzoyl, nitronaphthoyl, etc.), arenesulfonyl groups which may optionally have one or more suitable substituent(s) such as halogen (e.g. benzenesulfonyl, toluenesulfonyl, xylenesulfonyl, naphthalenesulfonyl, fluorobenzenesulfonyl, chlorobenzenesulfonyl, bromobenzenesulfonyl, iodobenzenesulfonyl, etc.), and so on.

The aromatic group-substituted aliphatic acyl groups may include ar(lower)alkanoyl groups which may optionally have one or more suitable substituent(s) such as lower alkoxy and trihalo(lower)alkyl (e.g. phenylacetyl, phenylpropionyl, phenylbutyryl, 2-trifluoromethyl-2-methoxy-2-phenylacetyl, 2-ethyl-2-trifluoromethyl-2-phenylacetyl, 2-trifluoromethyl-2-propoxy-2-phenylacetyl, etc.), and so on.

Among the above-mentioned acyl groups, the more desirable acyl groups are C₁-C₄ alkanoyl groups which may optionally be substituted by carboxy, cyclo(C₅-C₆)alkyloxy(C₁-C₄)alkanoyl groups having two (C₁-C₄)alkyl groups in the cycloalkyl moiety, camphorsulfonyl, carboxy(C₁-C₄)alkylcarbamoyl groups, tri(C₁-C₄)alkylsilyl(C₁-C₄)alkoxycarbonyl(C₁-C₄)alkylcarbamoyl groups, benzoyl which may have one or two nitro groups, halogen-substituted benzenesulfonyl groups, phenyl(C₁-C₄)alkanoyl groups having C₁ - C₄ alkoxy and trihalo(C₁ - C₄)alkyl groups. Of these groups, the most desirable are acetyl, carboxypropionyl, menthyloxyacetyl, camphorsulfonyl, benzoyl, nitrobenzoyl, dinitrobenzoyl, iodobenzenesulfonyl and 2-trifluoromethyl-2-methoxy-2-phenylacetyl.

Suitable "5- or 6-membered N-, S- or O- containing heterocyclic ring "may include pyrrolyl, tetrahydrofuryl, and the like.

The pharmaceutically acceptable salt of compound (I) is a nontoxic salt, which may be the corresponding salt with an inorganic or organic base such as alkali metal salts (e.g. sodium salt, potassium salt, etc.), ammonium salt and amine salts (e.g. triethylamine salt, N-benzyl-N-methylamine salt, etc.), and so on.

With regard to the compound (I) of the present invention, it is to be noted that there may be one or more than one conformers or stereoisomers such as optically or geometrically isomeric pairs due to the presence of one or more than one asymmetric carbon atom or double bond, and these are included within a scope of the compound (I) of the present invention.

It will hereinafter be described in detail how the present invention has completed, especially relating to the important point of the present invention i.e., the reason why a mixture of surface active agent and nonaqueous solvent is selected in this invention.

A liquidous pharmaceutical containing the compound (I) should be offered as a stable liquid as it is for the purpose of administrating to human body and transferring the effective amount of the ingredient compound to human body. Further on considering a special use such as intravenous injection that is the main object of the present invention, should be offered a whole clear liquidous pharmaceutical which can maintain the clarity under long term storage.

From the above point of view, the inventors of the present invention studied, at first, the solubility of the compound (I) in water. As a test compound, the inventors selected the following compound as a free form which has an excellent immunosuppressive activity and is called FK 506 hereafter.

5 R^1, R^2, R^8, R^{23} = hydrogen R^7, R^9 = hydroxy
 $R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{22}$ = methyl R^{10} = allyl
 $R^{20} = R^{20}a, H$ ($R^{20}a$ = methoxy) X, Y = oxygen
 $R^{21} = R^{21}a, H$ ($R^{21}a$ = hydroxy) n = 2
 10 R^3, R^4 = form a second bond between the vicinal carbon atoms to which they
 are attached
 15 R^5, R^6 = form a second bond between the vicinal carbon atoms to which they
 are attached

15 The solubility of FK 506 in water is at most 3μ g/ml under ambient temperature. Accordingly, it is decided to add a surface active agent in order to increase the solubility of FK 506 in water to the level where the clinically effective amount of FK 506 is dissolved. Table 1 shows the solubility of FK 506 under the different condition e.g., the kind and the concentration of a surface active agent and temperature. As a surface active agent, a castor oil-surface active agent i.e., HCO-10, HCO-40, HCO-60 (trademark, prepared by Nikko Chemicals, respectively) are selected for examination.

20 It is conjectured from the result shown in Table 1 that the concentration of the surface active agent should be controlled at 1.43w/v% [about 150mg of the surface active agent against 1mg of FK506] to dissolve 0.1mg of FK 506 in 1ml of water, calculating based on the result that 0.035mg of FK 506 is dissolved in 1ml of 0.5w/v% HCO-60 aqueous solution at 20 °C . Accordingly, if it is desired to prepare 25 5mg/ml aqueous solution FK 506, the concentration of the surface active agent is estimated to come up to 87w/v% from the calculation based on the result of HCO-60, 20w/v%, 20 °C . Such tolerably high concentration of surface active agent in aqueous solution should not be realized in practice of clinical field.

Table 1

Concentration of surface active agent (w/v %)	Kind of surface active agent and solubility of FK506 (mg/ml)				
	HCO-40	HCO-60		Mixture of HCO-60 and HCO-10 (4:1)	
	20 °C	20°C	30°C	20°C	30°C
0.1	—	0.005	—	—	—
0.3	—	0.019	—	—	—
0.5	—	0.035	—	—	—
5	0.40	0.28	0.29	0.26	0.27
10	0.78	0.61	0.57	0.56	0.56
20	1.52	1.15	1.14	1.13	1.14

HCO-60 : Polyoxyethylenehydrogenated Castor Oil 60

HCO-40 : Polyoxyethylenehydrogenated Castor Oil 40

HCO-10 : Polyoxyethylenehydrogenated Castor Oil 10

55 Table 2 shows a remaining percentage of FK 506 in aqueous solution wherein FK 506 is dissolved in water in the presence of large amount of surface active agent. From this table, it is found that the stability for long period storage is not expectable in the above prescription .

Table 2

Storage conditions	Remaining percentage of FK 506 (%) (prescription)	
FK 506	0.5mg	
HCO-60	100mg	
phosphoric acid buffer (pH 6)		1ml
Initial	100.0	
After 3days (at 40 °C)	52.7	
After 3days (at 80 °C)	42.2	

From the results of the above experiment, it is recognized that the use of surface active agent is not profitable means for the purpose of dissolving the compound (I), for example FK 506, in water.

Table 3 shows solubility of FK 506 in several kinds of nonaqueous solvent such as PEG (polyethylene glycol) 400, ethanol and propylene glycol. From the consideration of the illustrated data, it is found that FK 506 is dissolved in the experimented solvent at the concentration of more than 40mg/ml.

Table 3

Solvent	Solubility (at ambient temperature)
Ethanol	>300
PEG 400	>40
Propylene glycol	>40

(mg/ml)

Nonaqueous solvent is, at the time of administrating into the human vascular tract, usually diluted with aqueous solvent such as physiological saline, since nonaqueous solvent has hemolysis action. Therefore, the inventors of the present invention diluted the experimental solution by using nonaqueous solution (1ml) described in the following prescriptions 1 & 2 with physiological saline (100ml), and it was found that the nonaqueous solution became turbid at once and fine crystal of FK 506 was precipitated in a mixed medium.

(Prescription 1)

5 FK 506 10mg
Ethanol to 1ml

(Prescription 2)

10 FK 506 10mg
Propylene glycol to 1ml

Standing on the above result, the inventors of the present invention have then studied on combination use of nonaqueous solvent and surface active agent.

15 The experimental solution (1ml) of the following prescription 3 consisting of FK 506, surface active agent and nonaqueous solvent was diluted with physiological saline (100ml) to find that the clear appearance of prescription was kept unchange.

20 (Prescription 3)

FK 506 10mg
HCO-60 100mg
25 Ethanol to 1ml

Then several prescriptions of clear solution were further prepared altering the concentration of FK 506, the kind and the concentration of surface active agent, and were tested how change the clarity of the solution and whether separate out the crystal or not under the several condition of different degree of 30 dilution. The results thereof are shown in Table 4.

35

40

45

50

55

5
10
15
20
25
30
35
40
45
50

Cremophor[®] EL : trademark, prepared by BASF (Polyoxyethylen Castor Oil 35)

Table 4

Concentration of FK 506 (mg/ml)	Dilution times with physiological saline	Period till solution becomes turbid to crystallize FK506 (in days)					
		HCO-60	Cremophor [®] EL	HCO-40	80/20	40/60	80/20
5	2	≥7	≥7	≥7	≥7	≥7	≥7
	100	≥7	≥7	≥7	≥7	≥7	≥7
10	2	≥7	≥7	≥7	≥7	≥7	≥7
	100	≥7	≥7	≥7	≥7	≥7	≥7
25	2	≥7	≥7	≥7	≥7	≥7	≥7
	100	≥7	≥1	≥7	≥1	≥7	≥1
50	2	≥7	≥7	≥7	≥1	≥7	≥1

It is concluded from the result illustrated in Table 4 that a clear pharmaceutical solution which does not cause precipitation of the compound (I) on diluting with physiological saline can be prepared by controlling the ratio of the compound(I), surface active agent and nonaqueous solvent according to the kind of surface active agent under the condition that the concentration of the compound (I) is less than 50mg/ml.

Lastly it is tested the remaining percentage of FK 506 after storage in nonaqueous solvent containing

both FK 506 and surface active agent. In the test solution, the concentration of FK 506 is adjusted to 5mg/ml, and, for comparative a nonaqueous solution which contain only FK 506 is prepared. The experimental result is shown in Table 5.

5

Table 5

Storage conditions	Remaining percentage of FK 506(%) (prescription)		
	FK 506	5mg	
	HCO-60	400mg	
	ethanol	to	1ml
Initial	100.0		
80 °C	1 day	95.2	
	3 day	90.4	
	5 day	86.4	
	10 day	78.6	
	17 day	68.0	
60 °C	5 day	96.4	
	10 day	95.1	
	17 day	92.4	
	1 month	88.0	
40 °C	1 month	96.7	
	3 month	96.6	
	18 month	84.6	

It is concluded from the result shown in table 5 that HCO-60 is the most preferable surface active agent in the view point of storage stability.

As considered from the above experiments, the compound (I) such as FK 506 has quite poor solubility in water and this is not so improved even in the presence of surface active agent, and the storage stability especially at ambient temperature is quite inferior excepting that only frozen one can stand for some period of time.

In the mean time, it is found that the compound (I) is well dissolved in nonaqueous solvent. However it causes precipitation of the compound (I) on diluting with physiological saline to diminishing hemolysis action of nonaqueous solvent. Occurrence of precipitation makes it impossible to use in the clinical field.

Under the condition of cooperative use of nonaqueous solvent and surface active agent, it is noted that the compound (I) is well dissolved and there is no problem after long pereiod storage, and further it does

not happen to give any precipitate at the time of diluting with physiological saline.

The kind of nonaqueous solvent is not limited in the present invention, and any nonaqueous solvent may be used as much as it can dissolve the effective amount of the compound (I) and it may be acceptable in clinical use. The nonaqueous solvent may be used either alone or as a mixture thereof. Suitable examples thereof include ethanol, propylene glycol, glycerin, polyethylene glycol (e.g., PEG 400, PEG 300, PEG 200, etc.), or the mixture thereof from a view point of solubility and viscosity, etc. and most preferable one is ethanol. The representative examples of the surface active agent include, from a view point of storage stability for long term, a castor oil-surface active agents, and more preferable one is HCO (polyoxyethylene hardened oil)-surface active agents, and most preferable one is HCO-60, HCO-50 and the like. In addition to the above exemplified surface active agents, polyoxyethylene sorbitane fatty acid ester derivative (e.g., Polysorbate 80, etc.), glycerine fatty acid ester derivative (e.g., glycerine monocaprylate, etc.), polyethylene glycol fatty acid ester derivative (e.g., polyoxyethylene 40 monostearate, etc.), and the like may also be used.

The concentration of the compound (I) is determined from the judgement including the kind and the concentration of nonaqueous solvent and surface active agent, the composition ratio thereof, the stability after being diluted with physiological saline, etc. and storage stability. The suitable range of thus determined concentration is usually in the range of 0.1~ 50mg/ml and more preferably 1~ 20mg/ml.

As for the amount of surface active agent, it is noted to be less than the calculated estimation. From the experimental calculation based on the result illustrated in Table 1, about 150mg of the surface active agent may be necessary to obtain a saturated aqueous solution containing 1 mg of the compound (I) as stated above. However in the present invention the compound (I) is dissolved in a mixed solution of nonaqueous solvent - surface active agent - water to form stable supersaturation state, and therefore the necessary amount of surface active agent becomes less than the calculated one. These specific action, i.e., the low precipitating speed of the crystalline from the supersaturated solution, is based on the characteristic property of the compound (I). The range of the ratio of surface active agent to the compound (I) is preferably 1~ 100mg/1mg, and more preferably 30~ 60mg/1mg to prevent the occurrence of precipitation at the time of diluting for clinical use.

The pharmaceutical solution of the present invention may further contain, if necessary, other agent such as stabilizing agent, anodyne, and the like.

The pharmaceutical solution of the present invention is stable during long term storage and does not occur the precipitation of crystalline at the time of dilution. Therefore, this is applicable to various kind of medicine form such as intravenous injection, dropping lotion in the eye, dropping lotion in the nose, intraenteric injection, percutaneous liniment, local scattering agent, oral administration agent (e.g., syrup, etc.), and the like.

35

Example

Following prescriptions are shown only for the purpose of the explanation of this invention.

40

Prescription 1

FK 506	10mg
HCO-60	400mg
Ethanol	to 1ml

45

The solution comprising the ingredients stated above is prepared by dissolving the FK 506 and HCO-60 in ethanol by a conventional manner.

The following solutions are also prepared a similar manner of the Prescription 1.

50

55

Prescription 2

5	FK 506	5mg
	HCO-40	200mg
	PEG 400	to 1ml

Prescription 3

10	FK 506	2mg
	Polysorbate 80	50mg
	Propylene glycol	to 1ml

15
Prescription 4

20	FK 506	2mg
	Polysorbate 80	10mg
	Glycerine	0.5ml
	Ethanol	to 1ml

25
Prescription 5

30	FK 506	2mg
	HCO-60	20mg
	Propylene glycol	to 1ml

35

40

45

50

55

Prescription 6

FK 506	1mg
--------	-----

Polyoxyethylene (40) mono stearate	
------------------------------------	--

5

20mg	
------	--

Propylene glycol	to	1ml
------------------	----	-----

Prescription 7

10

FK 506	10mg
--------	------

HCO-60	400mg
--------	-------

Ethanol	to	1ml
---------	----	-----

15

Prescription 8

20

FK 506	5mg
--------	-----

HCO-60	400mg
--------	-------

Ethanol	to	1ml
---------	----	-----

Prescription 9

25

FK 506	25mg
--------	------

HCO-60	400mg
--------	-------

Ethanol	to	1ml
---------	----	-----

30

Prescription 10

35

FK 506	2mg
--------	-----

HCO-60	10mg
--------	------

Glycerine	0.5ml
-----------	-------

Ethanol	to	1ml
---------	----	-----

40

Effect of the Invention


Thus obtained nonaqueous pharmaceutical solution containing the compound (I) is stable during long term storage and does not occur any precipitation at the time of diluting with physiological saline, glucose solution for injection, water, fruit juice, milk, or the like for clinical use. Accordingly, the pharmaceutical solution of the present invention is applicable to various kind of medicine form such as intravenous injection, oral administration agent and the like, which could contribute the compound (I) in clinical field wherein its immunosuppressive activity is intensely desired. Particularly, the most preferable medicine form of the present nonaqueous pharmaceutical solution is the one for intravenous injection by diluting with the physiological saline.

50

Claims


1. A pharmaceutical solution comprises
a compound of the general formula

55



- 25 wherein each vicinal pair of substituents [R¹ and R²], [R³ and R⁴], [R⁵ and R⁶] independently
 a) represent two vicinal hydrogen atoms, or
 b) form a second bond between the vicinal carbon atoms to which they are attached ; in addition to its significance above, R² may represent an alkyl group ;
 R⁷ represents H, OH, protected hydroxy or O-alkyl, or in conjunction with R¹ it may represent =O ;
 30 independently represent H or OH ;
 R⁸ and R⁹ represents H, alkyl, alkyl substituted by one or more hydroxyl groups, alkenyl, alkenyl substituted by one or more hydroxyl groups, or alkyl substituted by =O ;
 R¹⁰ represents O, (H,OH), (H,H) or -CH₂O- ;
 35 X represents O, (H,OH), (H,H) or N-NR¹¹R¹² or N-OR¹³ ;
 Y independently represent H, alkyl, aryl or tosyl ;
 R¹¹ and R¹² independently represent H or alkyl ;
 40 R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³ independently represent O, or they may independently represent (R²⁰a, H) and (R²¹a, H) respectively ; R²⁰a and R²¹a independently represent OH, O-alkyl or OCH₂OCH₂CH₂OCH₃ or R²¹a is protected hydroxy ;
 45 in addition, R²⁰a and R²¹a may together represent an oxygen atoms in an epoxide ring ;
 n is 1, 2 or 3 ;
 in addition to their significances above, Y, R¹⁰ and R²³, together with the carbon atoms to which they are attached, may represent a 5- or 6- membered N-, S- or O-containing heterocyclic ring, which 50 may be saturated or unsaturated, and which may be substistuted by one or more groups selected from alkyl, hydroxy, alkyl substituted by one or more hydroxyl groups, O-alkyl, benzyl and -CH₂Se-(C₆H₅) ;
 or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable surface active agent and a pharmaceutically acceptable nonaqueous solvent.
- 55 2. The pharmaceutical solution of claim 1, wherein the compound (I) or a pharmaceutically acceptable salt thereof and the pharmaceutically acceptable surface active agent are in the ratio of 1:1 to 1:100 by weight.

3. The pharmaceutical solution of claim 2, wherein the pharmaceutically acceptable surface active agent is a castor oil-surface active agent.
4. The pharmaceutical solution of claim 3, wherein the pharmaceutically acceptable nonaqueous solvent is ethyl alcohol.
5. The pharmaceutical solution of claim 4, wherein the compound (I) is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23, 25-dimethoxy-13,19,21,27-tetramethyl-11, 28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone.
- 10 6. A process for preparing a pharmaceutical solution, which is characterizing by dissolving a compound of the formula :



wherein each vicinal pair of substituents [R¹ and R²], [R³ and R⁴], [R⁵ and R⁶] independently

- a) represent two vicinal hydrogen atoms, or
40 b) form a second bond between the vicinal carbon atoms to which they are attached ; in addition to its significance above, R² may represent an alkyl group ;

R⁷

represents H, OH, protected hydroxy or O-alkyl, or in conjunction with R¹ it may represent =O ;

independently represent H or OH ;

R⁸ and R⁹
45 R¹⁰
represents H, alkyl, alkyl substituted by one or more hydroxyl groups, alkenyl, alkynyl substituted by one or more hydroxyl groups, or alkyl substituted by =O ;

X
represents O, (H,OH), (H,H) or -CH₂O- ;

Y
represents O, (H,OH), (H,H) or N-NR¹¹R¹² or N-OR¹³ ;

R¹¹ and R¹²
50 R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³
independently represent H, alkyl, aryl or tosyl ;

R²⁰ and R²¹
independently represent H or alkyl ;

independently represent O, or they may independently represent (R²⁰a, H) and (R²¹a, H) respectively ; R²⁰a and R²¹a independently represent OH, O-alkyl or OCH₂OCH₂CH₂OCH₃ or R²¹a is protected hydroxy ;

55

EP 0 444 659 A2

in addition, R²⁰a and R²¹a may together represent an oxygen atoms in an epoxide ring ;
n is 1, 2 or 3 ;

5 in addition to their significances above, Y, R¹⁰ and R²³, together with the carbon atoms to which they are attached, may represent a 5- or 6- membered N-, S- or O-containing heterocyclic ring, which may be saturated or unsaturated, and which may be substituted by one or more groups selected from alkyl, hydroxy, alkyl substituted by one or more hydroxyl groups, O-alkyl, benzyl and -CH₂Se-(C₆H₅) ;

or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable surface active agent in a pharmaceutically acceptable nonaqueous solvent.

10

15

20

25

30

35

40

45

50

55

EP1064942

Publication Title:

SUSTAINED RELEASE PREPARATION of a macrolide

Abstract:

Abstract of EP1064942

Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.